

1 **Estimation of Lassa fever incidence rates in West Africa: development of a modeling framework to**
2 **inform vaccine trial design**

3

4 Sean M. Moore^{1,^,#}, Erica Rapheal², Sandra Mendoza Guerrero^{3,*}, Natalie E. Dean⁴, Steven T. Stoddard^{3,*}

5

6 ¹Department of Biological Sciences, University of Notre Dame, Notre Dame, IN USA

7 ²Independent Consultant

8 ³Emergent Biosolutions, Inc., Gaithersburg, MD USA

9 ⁴Department of Biostatistics & Bioinformatics, Emory Rollins School of Public Health, Atlanta, GA USA

10 [^] Current address: Division of International Epidemiology and Population Studies, Fogarty International
11 Center, National Institutes of Health, Bethesda, MD USA

12 ^{*} Current address: Bavarian Nordic, Inc., San Diego, CA USA

13 [#] Correspondence: smoore15@nd.edu

14

15 Short Title: Modeling Lassa fever to inform vaccine trial design

16 **Abstract**

17 *Background*

18 Lassa fever (LF) is an acute viral hemorrhagic disease endemic to West Africa that has been declared a
19 priority disease by the World Health Organization due to its severity and the lack of a vaccine or
20 effective treatment options. Several candidate vaccines are currently in development and are expected
21 to be ready for phase III field efficacy trials soon. However, most LF cases and deaths are believed to go
22 unreported, and as a result we lack a clear understanding of several aspects of LF epidemiology and
23 immunology that are critical to the design of vaccine efficacy trials.

24 *Methods*

25 To help guide vaccine trial design and site selection we estimated the force of infection (FOI) in all 1st
26 and 2nd administrative units in West Africa from published seroprevalence studies. We next estimated LF
27 reporting probabilities using these FOI estimates and LF case and death reports and then projected FOI
28 in all admin1 and admin2 areas without seroprevalence data. We then extrapolated age-specific LF
29 incidence rates from FOI estimates under different assumptions regarding the level of protection against
30 reinfection among seropositive and seronegative individuals with a history of prior infection.

31 *Results*

32 Projected FOI estimates and modeled annual LF incidence rates indicate that Sierra Leone, southern
33 Guinea, and a few areas within Nigeria would likely yield the highest LF case incidence rates during a
34 vaccine trial. Estimated LF incidence rates were highly sensitive to assumptions about Lassa
35 immunology, particularly the frequency of seroreversion among previously infected individuals and the
36 extent to which seroreverted individuals retain protection against reinfection and more severe disease
37 outcomes.

38 *Conclusions*

39 Our spatial LF incidence rate estimates, along with the interannual and seasonal variability in these
40 estimates and estimates of baseline seroprevalence, could be used for vaccine trial site selection,
41 choosing the target population (e.g., age and serostatus), and maximizing a trial’s statistical power.

42 **Author Summary**

43 Lassa fever virus infects an estimated 100,000-300,000 people and kills 5,000 people annually in West
44 Africa. Incidence rates appear to be highly spatially heterogeneous within the endemic region; however,
45 the true nature is uncertain due to significant surveillance gaps. We modeled Lassa Fever disease
46 incidence at a sub-national scale throughout West Africa to inform the design of vaccine efficacy trials.
47 We find considerable spatial heterogeneity in incidence rates, with the highest rates concentrated in
48 Sierra Leone, Guinea, and a few areas of Nigeria. Even though we estimate that <1% of infections are
49 reported, our estimates also indicate that using symptomatic LF as a primary endpoint will require tens
50 of thousands of trial participants to demonstrate vaccine efficacy. Our work highlights data gaps and
51 uncertainties related to the ecology and epidemiology of LASV that limit our ability to estimate and
52 predict disease incidence.

53

54 **Introduction**

55 Lassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa. LF is caused by infection
56 with Lassa virus (LASV), an arenavirus that circulates in rodent populations but can spill over to human
57 populations.¹ Transmission is thought to occur through human contact with rodents either due to
58 infestation of human residences or processing for food.² Importantly, direct human-to-human
59 transmission in nosocomial settings also occurs, creating a potential for wider spread of the virus to
60 naive populations.² Most LASV infections are presumed to be asymptomatic or result in mild disease,
61 but up to 20% can result in a severe, life-threatening hemorrhagic illness.² In these instances, case

62 fatality rates among clinical LF cases can reach 60%.¹ Previous studies have estimated that 100,000-
63 300,000 LASV infections and 5,000 LF deaths occur annually in sub-Saharan Africa. However, these
64 estimates were extrapolated from limited serological studies conducted decades ago and may not
65 accurately reflect current conditions across West Africa.^{3,4}

66 Despite its severity and burden, there are currently few therapeutic options for LF and no licensed
67 vaccines.¹ In 2018, the World Health Organization (WHO) declared LF a 'Priority Disease,' and the
68 Coalition for Epidemic Preparedness Innovations (CEPI) subsequently invested in the development of six
69 LF vaccine candidates, four of which have entered clinical trials.¹¹ Individuals previously infected with
70 LASV maintain LASV-specific CD4+ memory T cells for years after the infection has cleared.⁶ This, along
71 with animal vaccination models, suggests that vaccination will provide meaningful protective immunity
72 against severe LF.¹² However, there are currently no immunological correlates of protection against LF
73 and the risk of severe disease rules out the option of controlled human infection studies to evaluate the
74 clinical benefit of a candidate vaccine.¹³ Instead, field efficacy trials are necessary to determine the
75 efficacy of vaccine candidates.

76 Assuming a primary endpoint of PCR-positive symptomatic LF disease, CEPI has targeted a minimum
77 annual LF incidence rate of 1% to ensure an adequately powered trial. An ideal study site will have a
78 baseline seroprevalence that indicates the presence of frequent LASV spillover, but which is low enough
79 that existing immunity in the population does not substantially reduce the LF incidence rate. Identifying
80 populations in which these criteria are likely to be met is the most critical consideration in Lassa vaccine
81 trial design.^{7,8} However, our understanding of Lassa epidemiology is limited by a lack of good prospective
82 epidemiological data and inconsistent disease surveillance across West Africa. Since 2018, reported LF
83 case counts have increased dramatically, although this is partly due to changes in surveillance and
84 diagnostics.⁵ Other than a couple of prospective community studies in Sierra Leone and Mali that tested
85 individuals for evidence of a recent LASV infection,^{3,7} and a few hospital-based surveillance studies of

86 severe LF cases,^{8,9} most epidemiological data on Lassa come from national surveillance programs. A
87 majority of LF cases are not detected by current clinical surveillance systems because common LF
88 symptoms—such as fever, malaise, headache, and muscle pain—closely resemble those of other febrile
89 illnesses endemic to the region.^{1,2,11} In addition, the extent of national LF surveillance varies considerably
90 from country to country in West Africa, complicating comparisons of incidence rates between different
91 LF-endemic areas. For example, Nigeria has expanded LF surveillance over the past decade,^{5,12} while
92 changes in healthcare-seeking behaviors in areas of Sierra Leone heavily impacted by the 2013-2016
93 Ebola virus epidemic have led to declines in the detection of febrile illnesses, including LF.^{9,13}
94 Because of the limited availability of epidemiological data for Lassa, in 2020 CEPI initiated a long-term,
95 multi-country, prospective epidemiological study of Lassa disease and infection in West Africa.¹⁴ This
96 study, called Enable, is tracking over 20,000 participants across five West African countries with the goal
97 of identifying baseline seroprevalence, LASV infection rates, LF incidence rates, serological dynamics,
98 and individual and community-level risk factors for infection and disease. Due to the impact of the
99 COVID-19 pandemic, data from the Enable study have not yet been published. However, preliminary
100 findings from the study presented in an interim report suggest that LASV infection is common in several
101 of the study locations and that prior infection does not confer lifelong immunity.¹⁵ Epidemiological data
102 such as those being collected in Enable are essential for understanding the current status of Lassa in the
103 region. In the absence of detailed epidemiological data across the entire geographic range of LF,
104 statistical models can be used to anticipate the future disease incidence for the purpose of vaccine trial
105 planning. Such a modeling framework, based on existing epidemiological data and accounting for the
106 factors that drive pathogen transmission and infection risk, can incorporate new epidemiological data
107 from Enable and other studies as it becomes available. This framework can include ecological factors
108 that influence the spatial and temporal patterns of disease and immunological factors related to
109 immunity.

110 LASV is thought to infect humans through exposure to the urine or feces of the multimammate rat,
111 *Mastomys natalensis*, which serves as the primary reservoir host.¹⁶ As a result, LASV spillover typically
112 occurs seasonally in rural and peri-urban areas of West Africa where agricultural practices,
113 socioeconomic factors, and the built environment promote rodent-human interactions.^{17–19} Field studies
114 have identified several risk factors associated with *M. natalensis* abundance in villages and individual
115 houses, but have also found that *M. natalensis* abundance and LASV seropositivity in rodents are
116 spatially heterogeneous at multiple spatial scales, from the village- to the subnational-level.^{20–22}
117 Moreover, incidence of disease can be markedly seasonal on broad spatial scales, suggesting important
118 variation in either rodent infection rates or contact with humans. Overall, the substantial spatial and
119 temporal variation in LASV prevalence is an important consideration for vaccine trial site selection, as
120 potential trial locations might have different LF incidence rates despite their proximity and similar
121 environmental conditions.

122 Because of the scarcity of longitudinal data, it is difficult to assess LF incidence, the duration of immunity
123 following infection, or reinfection rates. Two longitudinal serology studies have found evidence that 3-
124 6% of seropositive individuals seroreverted from IgG+ to IgG- between sampling periods, suggesting that
125 infection-induced immunity may not be permanent.^{23,24} Preliminary data from CEPI's Enable study also
126 indicate that seroreversion occurs relatively frequently.¹⁴ A further complication for our understanding
127 of LASV infection rates is that the frequency of severe LF following infection is uncertain. It is typically
128 stated that 80% of Lassa fever infections are asymptomatic, but data supporting this assumption is
129 extremely limited.²

130 Reliable estimates of sub-national LF incidence rates and baseline population-level immunity are needed
131 to inform trial site selection and enable successful LF vaccine efficacy trials. In lieu of detailed
132 geographical measurements, these epidemiological indicators can be modeled from available incidence
133 and seroprevalence data. Here, we use an epidemiological model to estimate LASV spillover rates and

134 the annual number of community-level LF cases at the 1st and 2nd administrative levels across West
135 Africa. We provide sub-national estimates of baseline seroprevalence and expected age-specific LF
136 incidence rates to help guide trial selection. We also explore the sensitivity of our estimates to different
137 assumptions of LF immunology, including the proportion of infections that are symptomatic, the level of
138 protection provided by prior infection, and the duration of this protection.

139 **Methods**

140 *Model development*

141 We integrated publicly available epidemiological data into a unified modeling framework for LF in West
142 Africa. We applied this model to investigate key questions regarding vaccine trial design including the
143 expected incidence rates for trial endpoints of disease and infection, the target population (e.g.,
144 geographical location, age range, and serostatus of participants), and sample size considerations
145 (number of sites, number of enrollees). The model was adapted from an existing model originally
146 designed to predict spillover of LASV and model reactive vaccination strategies during an LF outbreak.⁶¹
147 To better understand the magnitude and spatiotemporal distribution of LASV spillover rates and LF
148 incidence in endemic areas, we refined the model to focus on estimating the annual force of infection
149 (FOI), the rate at which susceptible individuals in a population are infected. The updated model also
150 incorporates the potential for seroreversion (seropositive individuals becoming seronegative over time
151 due to antibody waning). FOI estimates at the 1st and 2nd administrative levels were used to estimate
152 seasonal and interannual LF incidence rates across the study region. Rates were investigated in different
153 potential target populations defined by serostatus and age.


154 *a. Epidemiological data*

155 In our epidemiological model, we included 14 West African countries (Senegal, Gambia, Guinea-Bissau,
156 Guinea, Sierra Leone, Liberia, Côte D'Ivoire, Ghana, Benin, Togo, Nigeria, Niger, Burkina Faso, and Mali),

157 plus the administrative districts in Cameroon bordering Nigeria, which encompasses the known range of
158 LASV (Figure 1). Given the extensive spatial heterogeneity in LF incidence, we collated epidemiological
159 data at the 1st and 2nd administrative levels (admin1 and admin2) in each country within the study
160 region. For example, in Nigeria admin1 is the state level and admin2 is the local government area (LGA)
161 level; in Sierra Leone admin1 corresponds to the province level and admin2 is the district level. The
162 epidemiological data included in the study comprised two types: (a) age-stratified serology data to
163 detect evidence of past infection and (b) reports of suspected and confirmed LF cases and deaths in
164 humans. Epidemiological data was initially collated through the end of 2020 from multiple sources
165 (including WHO outbreak reports, ProMED reports, country-level reports, and a literature search) and
166 used in a previous analysis (see Table S1 in Lerch et al. 2022).⁶¹ For the current analysis we searched the
167 same sources for additional datasets through early 2023. We excluded seroprevalence studies from
168 before 1980 or where the location of the study population could not be identified at a sub-national
169 level. We also excluded seroprevalence studies that focused only a specific target population (generally
170 healthcare workers) that may not be representative of the overall population in the study area due to
171 unequal exposure to spillover or human-to-human transmission. All included studies were aggregated to
172 the admin1 and admin2 levels.

173 Where possible, case data was categorized into cases of documented or suspected human-to-human
174 transmission, documented or suspected spillover cases, and cases of unknown origin. Cases of
175 documented or suspected human-to-human transmission were excluded from the estimation of
176 spillover rates. Only cases and deaths from 2010-2023 were included in our analysis, because the
177 case/death data were used to estimate the fraction of LF cases that are reported and LF surveillance
178 systems have changed substantially in the past decade.^{5,62} Yearly, age-specific country-level population
179 data from 1960-2015 were obtained from UN World Population Prospects estimates and downscaled to
180 the admin1 and admin2 levels using population raster data from Worldpop.^{64, 63}

181



182

183 **Figure 1. Study region covering the hypothesized zone of Lassa fever (LF) endemicity.** Areas in orange
184 are (A) 1st administrative level units and (B) 2nd administrative level units that have reported LF cases or
185 deaths from 2010-2023. In some locations, data were only reported at the 1st administrative level.

186 *b. Covariate data*


187 To identify population-level covariates associated with LF occurrence, we used spatial datasets of
188 environmental, climate, and socioeconomic variables that have been hypothesized to be associated with
189 LF occurrence or transmission.^{8,31,40,42,43,51,53,64,65} These variables included monthly precipitation, monthly
190 average temperature, monthly normalized difference vegetation index (NDVI), elevation, latitude,
191 longitude, travel time to the nearest urban center,⁶⁶ the Healthcare Access and Quality Index (HAQ)

192 based on mortality from causes amenable to personal health care,⁶⁷ proportion of land cover that was a
193 tropical ecotype⁶⁸, proportion of agricultural land,⁶⁹ average forest loss over the past 20 years,⁷⁰ an
194 improved housing measure,⁷¹ a poverty index (percentage of households with an International Wealth
195 Index value below 35),⁷² the occurrence of hunting for bushmeat,⁷³ the probability of *Mastomys*
196 occurrence,²⁵ and the probability of LASV occurrence in *Mastomys* (Table S2).²⁵ Each covariate was
197 averaged to the admin1 and admin2 level. Within the study region, the improved housing measure or
198 *Mastomys* occurrence data was missing for some administrative units in northern Senegal, Mali, and
199 Niger, where there is no evidence of LF occurrence, so these administrative units were excluded from
200 our analysis. To reduce the number of variables in our regression models we performed principal
201 component analyses for monthly precipitation, monthly temperature, and monthly NDVI using the
202 ‘prcomp’ function in R. The first two principal components (PCs) for NDVI explained >90% of the
203 variation in monthly NDVI, and the first three PCs for precipitation and temperature each
204 explained >90% of the variation for these two variables, so these PCs were used in place of the monthly
205 values in subsequent analyses.

206 c. Model

207 A multistep process was used to model LF attack rates from recent epidemiological data: (1) estimation
208 of the recent force of infection (FOI) in administrative units with available seroprevalence data, (2)
209 estimation of the proportion of LF cases and deaths that were detected and reported in administrative
210 units using both seroprevalence data and case/death data, (3) estimation of the annual LASV spillover
211 infection rate in all administrative units with case/death data based on the underreporting estimates
212 from the previous step, (4) projection of the annual FOI for these administrative units based on these
213 spillover rates, (5) calculation of the population-level infection history in each administrative unit based
214 on these FOI estimates, (6) calculation of age-specific infection attack rates and LF incidence rates in
215 each administrative unit under several different scenarios regarding the rates of seroreversion and the

216 susceptibility to infection and disease among seropositive and seroreverted individuals (Table 1, Figure
217 2). This modeling process was conducted at both the 1st and 2nd administrative levels. In addition, we
218 used statistical and machine learning methods to estimate annual FOI in each administrative unit based
219 on the covariates in Table S2 and compared these estimates to the model projections from step 4. This
220 analysis was conducted to determine whether environmental variables associated with LF occurrence
221 could be used to estimate LASV spillover in the absence of human serology or case data. A brief
222 description of each step in this process is provided below, with additional details of the complete
223 process provided in the supplementary materials (S1 Appendix).



225 **Figure 2. Modeling framework schematic.** Our modeling framework involved seven sequential steps
226 that result in a set of ensemble models of the FOI and annual incidence of LF in each of the 1st and 2nd
227 administrative levels across West Africa. FOI estimates were projected and estimated for three different
228 seroreversion rates, and LF incidence rates were estimated for 18 scenarios: 3 different seroreversion
229 rates, 3 different assumptions about the susceptibility of seropositive individuals to disease, and 2
230 different assumptions about the susceptibility of seroreverted individuals to disease.

231

232 1. *Estimating the Force of Infection from Serology Data*

233 Estimates of the annual FOI were obtained for each 1st or 2nd level administrative unit where serological
234 data were available from 1980 - 2023 using a catalytic model and assuming a constant FOI (λ) over time.
235 We estimated FOI assuming either a 0%, 3% (observed in Mali by Safronetz et al. 2017),⁷ or 6%
236 seroreversion rate (observed in Sierra Leone by McCormick et al. 1987).²³ In the absence of
237 seroreversion, and assuming all infected individuals develop detectable antibody levels following
238 infection, the proportion of a population that will be seropositive at age a is determined by the FOI (λ):

$$239 \quad p(a) = 1 - e^{-\lambda a}. \quad (1)$$

240 If antibodies wane over time and some individuals serorevert from IgG+ to IgG-, then the proportion of
241 the population seropositive at age a can be estimated using a reverse catalytic model:

$$242 \quad p(a) = \frac{\lambda}{\lambda + \pi} (1 - e^{-(\lambda + \pi)a}), \quad (2)$$

243 where π is the annual seroreversion rate. Equation (2) simplifies to equation (1) when $\pi = 0$.

244 Serology data for FOI estimation was obtained for 24 1st-level administrative units and 53 2nd-level
245 administrative units. Additional details regarding how FOI was estimated from serology data are
246 provided in S1 Appendix.

247 **2. Estimating Country-specific Reporting Fractions**

248 For each administrative unit where the FOI was estimated from serology data in the previous step, we
249 estimated the fraction of infections that went unreported from 2010-2023 based on the discrepancy
250 between reported LF cases and deaths and the annual number of infections predicted by the FOI
251 estimates from those sites under the three different seroreversion scenarios. We first estimated the
252 location-specific fraction of infections that went underreported, the fraction that resulted in a reported
253 LF case, and the fraction that resulted in a reported LF death using a method adapted from Perkins et al.
254 (2021).⁷⁴ The estimation process was repeated using 1000 draws from the posterior FOI estimates from
255 step 1 to generate posterior distributions for the reporting fractions. Country-specific reporting fractions
256 were then estimated from all available admin1 or admin2 level estimates within each country and used
257 to extrapolate infections from LF case and death data in locations without serology data in step 3.

258 **3. Estimating LASV spillover rates**

259 For each administrative unit, we next estimated the total number of annual infections, I_{it} , based on the
260 reported LF cases and deaths from 2010-2023 along with the estimated reporting fractions from the
261 previous step using maximum likelihood estimation.

262 **4. Projecting the FOI from estimated LASV spillover rates**

263 For each administrative unit where LASV spillover infections were estimated from LF case/death data in
264 step 3, we then projected the underlying FOI that would correspond to the estimated infection rate. The
265 projected FOI_{*i*} for each administrative unit *i* was obtained by minimizing the difference between the
266 number of infections, I_i , estimated in the previous step and the expected number of infections arising
267 from a given FOI in the reverse catalytic model from equation (2) using the *optim* function in R. This
268 resulted in a posterior distribution of FOI_{*i*} for each admin1 and admin2 unit.

269 **5. Estimation of Population-level Infection Histories**

270 The FOI projections generated from serology and case data in step 4 were then used to simulate
271 population-level infection histories for each admin1 and admin2 unit. For the FOI projections, we drew
272 1,000 samples for each administrative unit from the posterior distribution and computed the proportion
273 of the population that had been infected by age a using the catalytic model in equation (1), and the
274 proportion of the population seropositive at age a using the reverse catalytic model in equation (2) for
275 the three different seroreversion rates.

276 *6. Estimating LASV Infection and LF Attack Rates*

277 The inferred population-level infection histories and FOI estimates were then used to compute the
278 expected number of infections in each admin1 or admin2 administrative unit. We examined several
279 different scenarios regarding the risk of seropositive or seroreverted individuals becoming reinfected
280 and developing LF (Table 1). Reinfection of seropositive individuals, as defined by a fourfold increase in
281 antibody titers, was observed in Sierra Leone by McCormick et al. (1987) and in the preliminary results
282 from the ongoing Enable study.^{27,14} In addition, the Enable study reported LF cases among individuals
283 who were seropositive at baseline, indicating that prior infection does not entirely protect an individual
284 from developing disease if they are reinfected (unpublished data).¹⁴ Therefore, we considered three
285 scenarios for the susceptibility of seropositive individuals to symptomatic infection: (a) no risk, (b) a
286 reduced risk informed by the rates of infection observed in seronegative vs. seropositive individuals
287 observed by McCormick et al. (1987) and Enable (relative risk (RR) = 0.53), or (c) a reduced risk informed
288 by the relative rates of LF cases observed in individuals who were seropositive vs. seronegative at
289 baseline in the Enable study (RR=0.36).

290 Table 1. Immunological parameters included in model sensitivity analysis, and the low, medium, and
291 high values considered for each parameter. Lassa fever relative risk values are in comparison to fully
292 susceptible individuals with no history of LASV infection.

Parameter	Low	Medium	High
Seroreversion rate	0% / yr	3% / yr	6% / yr
Lassa fever relative risk (seropositive individuals)	0	0.36	0.53
Lassa fever relative risk (seroreverted individuals)	0.53	-	1

293

294 Although simple reverse catalytic models generally assume that seroreverted individuals are susceptible
295 to reinfection, an individual may still have protection against developing moderate or severe disease
296 even if their antibody titers have dropped below the detectable limit. At present this possibility has not
297 been addressed for LASV, so we considered two scenarios: (a) seroreverted individuals are completely
298 susceptible to reinfection and illness, and (b) seroreverted individuals can be reinfected but have a
299 reduced probability of developing LF based on the reduced rate of reinfection experienced by
300 seronegative vs. seropositive individuals (RR=0.53).

301 Including our three seroreversion rate scenarios, we therefore consider a total of 18 (3x3x2) scenarios
302 regarding the role of immunity in modulating susceptibility and influencing LF attack rates. The expected
303 annual number of infections in administrative unit i were calculated from the FOI_i using the reverse
304 catalytic model in equation (2) for each of the 18 different scenarios at both the admin1 and admin2
305 levels. The number of infections was multiplied by the symptomatic probability (20%) to obtain an
306 estimate of the expected annual number of LF cases in each administrative unit.

307 To account for the observed seasonality in human LF cases, we fit a beta distribution to the timing of
308 reported LF cases in Nigeria, Liberia, and Sierra Leone, and simulated the timing of LF cases as a random

309 draw from that distribution. For countries where we could not estimate seasonality, we assumed an
310 average of the observed seasonality in Nigeria, Liberia, and Sierra Leone.

311 *Modeling the FOI from covariate data*

312 There is a large degree of uncertainty in the estimated spillover rates for administrative units that have
313 reported only a small number of LF cases due to the large proportion of asymptomatic infections and
314 low reporting probabilities. Therefore, we used several statistical models to explore the relationships
315 between our FOI estimates from step 4 and several key spatial covariates (Table S2). These statistical
316 regression models were fit to the projected FOI_i estimates from administrative units with either serology
317 data or reported LF case/death data (N=77 of 164 admin1s, N=372 of 1,375 admin2s). The fitted models
318 were then used to predict FOI in the administrative units with no serology or case data.

319 Given that we have limited historical data and high uncertainty in our projected FOI estimates, we
320 considered eight different statistical models, as well as a null model with a single FOI estimated across
321 all administrative units. For each seroreversion scenario, we generated an ensemble model projection of
322 FOI in each admin1 or admin2 from the eight statistical models. Ensemble weights for each of the eight
323 models were calculated based on the performance of the individual model at predicting data withheld
324 from the model fitting step using a ten-fold cross-validation technique. Further details on the individual
325 statistical models and the ensemble approach are presented in S1 Appendix.

326 **Results**

327 *Literature review*


328 Thirty-one papers were selected for in-depth literature review. Topics of interest were Lassa serology (n
329 = 12), rodent epidemiology (n = 10), environmental risk factors and seasonality (n = 5), and LF
330 incidence/symptomatic rates (n = 4). Studies took place in Sierra Leone (n = 7), Guinea (n = 7), Nigeria (n
331 = 10), Ghana (n = 1), and Mali (n = 3). Three studies included all LF cases in Africa or globally (including

332 imported cases). Most studies were published in the last 10 years ($n = 21$). Seven studies were published
333 between 2000 and 2013, and three studies were from before 2000. LASV IgG seroprevalence varied
334 from 4% to 60%; in general, rates were higher in forest and savannah regions and lower near the coast
335 and in the highlands.^{40–43} Seroprevalence in rodents is similarly variable, with IgG positivity between 6–
336 52%,^{29,53–56} and PCR positivity between 1–87%.^{58,59} One study in Guinea found that individual villages
337 showed some interannual variation in rodent seropositivity, but that all villages studied maintained at
338 least 20% positivity from year to year.⁵⁷ Studies of seroreversion rates in Sierra Leone and Mali found 6
339 and 3% of seropositive individuals, respectively, reverted to seronegative in a given year.^{23,29} It is
340 typically assumed that 80% of Lassa fever infections are asymptomatic, but data supporting this
341 assumption is extremely limited. All studies included are shown in Table S1.

342 *FOI estimates from serology*

343 The FOI was estimated from serology data available from 1980–2023 for 24 1st-level administrative units
344 and 53 2nd-level administrative units. FOI was estimated for at least one administrative unit in Côte
345 d'Ivoire, Ghana, Guinea, Liberia, Mali, Nigeria, and Sierra Leone (Figure 3). Under the assumption of no
346 seroreversion, the highest FOI at the admin1 level was in Ondo State, Nigeria (0.036/yr; 95% Credible
347 Interval (CrI): 0.027–0.047) and the highest FOI at the admin2 level was in Moyamba District, Sierra
348 Leone (0.063/yr; 95% CrI: 0.042–0.090) followed by Ose LGA in Ondo State, Nigeria (0.052/yr; 95% CrI:
349 0.037–0.071). The FOI estimates assuming annual seroreversion rates of 3% or 6% were higher than FOI
350 estimates without seroreversion. Ondo State, Nigeria remained the highest FOI at the admin1 level, with
351 the estimate increasing to 0.065 (95% CrI: 0.047–0.086) with a 3% seroreversion rate and 0.099/yr (95%
352 CrI: 0.071–0.133) with a 6% seroreversion rate. At the admin2 level Ose LGA, Nigeria had the highest FOI
353 estimate with 3% or 6% seroreversion rates, followed by Moyamba District, Sierra Leone and Esan West
354 LGA in Edo State, Nigeria.

355



356

357 **Figure 3. Map of areas with Lassa fever (LF) serology data.** Blue areas are (A) 1st administrative level

358 units and (B) 2nd administrative level units where age-specific serology data was available.

359 *Estimates of underreporting*

360 Estimates of the probability that a LASV infection would be reported as an LF case were estimated for

361 each of the countries with serology and LF case data (Côte d'Ivoire, Ghana, Guinea, Liberia, Mali, Nigeria,

362 and Sierra Leone). In addition, we estimated the average reporting probability across the study region,


363 which was used to estimate LASV infections and FOI in countries that did not have serology data. Due to

364 the higher FOI estimates with seroreversion, the probability of a LASV infection being reported was
365 highest when we assumed no seroreversion and lowest with a seroreversion rate of 6%. Assuming a 6%
366 seroreversion rate, the average probability that a LASV infection would be reported as a LF case or death
367 at the admin1 level was 0.18%. The country-specific reporting probability ranged from a low of 0.20% in
368 Ghana and Guinea, to a high of 1.08% in Nigeria. At the admin2 level, the average probability that a
369 LASV infection would be reported as a LF case or death was 2.1%. This higher reporting probability was
370 largely driven by the results of one serology study that found low seroprevalence in two LGAs in Edo
371 State, Nigeria that are considered transmission hotspots.⁷⁵

372 *FOI projections from LF case data and reporting probabilities*

373 The projected FOI estimates from LF case data and estimated country-specific reporting probabilities
374 varied considerably across the study region, with evidence of spatial heterogeneity within and between
375 countries (Figure 4, Figures S1-S2). In particular, there was substantial heterogeneity in FOI estimates at
376 the admin1 and admin2 levels within Nigeria. Because serology data were only available for 3 out of 774
377 LGAs within Nigeria (admin2), these FOI estimates are primarily informed by the LF case and death data,
378 which also shows significant spatial variability (e.g., see Redding et al. 2021).⁶⁴ The magnitude of FOI
379 estimates, but not their spatial distribution, varied with the seroreversion rate.

380



381

382

383 **Figure 4.** Maps of FOI projections from LF case/death data and reporting probabilities at the (A) 1st and

384 (B) 2nd administrative levels with seroreversion = 6%.

385

386 *Estimates of FOI from individual statistical and ensemble models*

387 Among the statistical and machine learning models we explored to characterize the explanatory value of

388 the covariates in Table S2, the random forest model provided the best fit to the projected FOI estimates

389 at the admin1 level ($r^2=0.95$), followed by the boosted regression model ($r^2=0.78$; Figure 5, Figure S3). At


390 the admin2 level, the random forest model again provided the best fit ($r^2=0.96$), followed by the linear

391 model with interactions ($r^2=0.83$; Figure S4). The Gaussian Markov random field (GMRF) models with
392 covariates also fit the projected FOI estimates better than GMRF models without covariates (Figures S3-
393 S4) suggesting that the covariates provide some useful information. At the admin1 level, the most
394 important covariates in the random forest model were longitude, travel time to the nearest urban
395 center, and the Healthcare access and quality index (HAQ) (see Table S3 for full list of covariate
396 importance). center, and the estimated probability of LASV presence in *Mastomys natalensis* (Table S4).
397 At the admin2 level, the most important covariates in the random forest model were longitude, HAQ,
398 and the 2nd precipitation PC (Table S5). The performance of the model predictions on data held out of
399 the regression for model validation was much lower for the 1st administrative level, with random forest
400 providing the best fit to the testing data ($r^2=0.32$), suggesting that the models are overfitting to the
401 training dataset (Figure S5). The cross-validation performance of most regression models was better at
402 the 2nd administrative unit, with the random forest model providing the best fit ($r^2=0.76$), and the
403 boosted regression and GMRF models with and without covariates all maintaining an $r^2>0.70$ (Figure S6).
404 The low ratio of data points per covariate at the admin1 level may explain the poor cross-validation
405 performance relative to the admin2 level (N=77 for admin1 vs. N=372 for admin2).

406 Our ensemble model consisted of a weighted combination of the FOI predictions of each individual
407 statistical regression model, along with a noise term. The ensemble model FOI estimates at the 2nd
408 administrative unit (Figures S7-S9) show much less spatial heterogeneity than the projected FOI
409 estimates from LF case data and reporting probabilities (Figure 4B). This largely results from the higher
410 weighting of the GMRF models, which include spatial smoothing (45.7% combined among the four
411 GMRF models). This spatial smoothing results in lower FOI estimates in the few projected Nigerian
412 hotspots, and lower within- and among-country variation in FOI estimates overall. Further details on the
413 results of the statistical and ensemble modeling are presented in the supplement (SI Results).

414

415



416

417 **Figure 5.** Scatterplots showing the relationship between the statistical regression predictions of FOI on
418 the x-axis versus the FOI estimates projected from LF case data and reporting probabilities for the best
419 performing statistical models included in our analysis. (A) Results of random forest model, and (B)
420 results of boosted regression tree model. Plots are restricted to FOI estimates that were used in model
421 fitting and do not include data held out for model validation. Results are for the 1st administrative level
422 and a 6% seroreversion rate. Grey lines around points represent error bars for both direct and
423 regression estimates of FOI values.

424

425 *LASV infection attack rates and LF incidence rates*

426 Due to the positive association between the assumed seroreversion rate and FOI, the highest LASV
427 infection attack rates and LF case incidence rates occurred in scenarios with a seroreversion rate of 6%.
428 For a given seroreversion rate, LF case incidence rates were lowest when seropositive individuals were
429 assumed to be protected from infection, intermediate when they had a relative risk of 0.36 for

430 developing LF compared to seronegative individuals, and highest when they had a relative risk of 0.53
431 for reinfection and disease. When seroreverted individuals were assumed to have partial protection
432 against LF, incidence rates were lower than when seroreverted individuals were assumed to be fully
433 susceptible. Therefore, estimated LF incidence rates were highest when we assumed that seroreversion
434 was frequent (6%), and that both seroreverted and seropositive individuals remained susceptible to
435 infection and disease.

436 Due to the spatial heterogeneity in our FOI estimates, the highest LF incidence rates were found at the
437 admin2 as opposed to the admin1 level. No admin1 units had an LF incidence rate of greater than 10 per
438 1,000 (1%) with a 0% or 3% seroreversion rate, and only Ondo State in Nigeria had an LG incidence
439 rate >10/1,000 at a 6% seroreversion rate based on our projected FOI estimates (Table 2 and Tables
440 S7,S9). In general, there was a wider range of annual LF incidence rates with the projected FOI
441 estimates than the ensemble model FOI estimates, due to the smoothing effects of the ensemble model.
442 For example, no Nigerian states were in the top-20 using the ensemble model estimates despite Ondo,
443 Ebonyi, and Edo States all being in the top-20 based on the projected FOI estimates. Due to the over-
444 smoothing effect observed in the ensemble model, we focus on LF incidence rates derived from the
445 projected FOI estimates in the rest of our results.

446 At the 2nd administrative level, LF incidence rates calculated from projected FOI estimates were >10 per
447 1,000 for several administrative units with seroreversion rates of 3% or 6%, but not 0% (Table 3 and
448 Tables S8,S10). While the influence of different assumptions regarding the susceptibility of seropositive
449 and seroreverted individuals to LF was minor at lower incidence rates, their impact is more apparent for
450 the admin2 units with the highest incidence rates (Table 3). For example, for Ose LGA, Nigeria, the
451 admin2 with the highest FOI, the median annual LF incidence rate increased from 9.7 per 1,000 when
452 seropositive individuals had full immunity and seroreverted individuals had partial protection, to 12.4
453 per 1,000 when seropositive individuals were fully immune but seroreverted individuals had no

454 protection, to 24.7 per 1,000 when seropositive individuals were only partially immune and
455 seroreverted individuals had no protection. Four admin2 units (two in Sierra Leone, one in Nigeria, and
456 one in Guinea) had LF incidence rates <10 per 1,000 when seropositive individuals were fully protected,
457 but incidence rates above 10 per 1,000 when we assume seropositive individuals were susceptible to
458 reinfection and illness.

459 **Table 2. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is**
460 **6%.** LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in
461 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Country	Admin1	Annual Lassa Fever incidence rate (per 1,000)					
		Seroreverted – No Immunity			Seroreverted – Partial Immunity		
		Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)	Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)
Nigeria	Ondo	9.6 (8.1 – 11.0)	12.9 (10.1 – 16.0)	14.5 (11.1 – 18.6)	7.8 (6.7 – 8.7)	11.1 (8.7 – 13.8)	12.7 (9.7 – 16.3)
Mali	Sikasso	7.1 (6.3 – 7.8)	8.3 (7.3 – 9.4)	9.0 (7.7 – 10.3)	6.1 (5.5 – 6.6)	7.4 (6.5 – 8.3)	8.0 (6.9 – 9.1)
Guinea	Farannah	6.3 (5.9 – 6.8)	7.5 (6.8 – 8.1)	8.0 (7.3 – 8.8)	5.4 (5.0 – 5.7)	6.5 (6.0 – 7.0)	7.1 (6.4 – 7.7)
Sierra Leone	Southern	6.0 (4.9 – 7.0)	7.0 (5.5 – 8.5)	7.5 (5.8 – 9.2)	5.1 (4.3 – 5.9)	6.1 (4.9 – 7.3)	6.6 (5.2 – 8.0)
Cote d'Ivoire	Lacs	5.1 (3.8 – 6.3)	5.7 (4.1 – 7.4)	6.0 (4.3 – 8.0)	4.4 (3.4 – 5.4)	5.1 (3.8 – 6.5)	5.4 (3.9 – 7.0)
Guinea	Nzerekore	4.3 (4.1 – 4.5)	4.8 (4.5 – 5.0)	5.0 (4.7 – 5.3)	3.9 (3.7 – 4.0)	4.3 (4.1 – 4.5)	4.5 (4.3 – 4.8)

Sierra Leone	Eastern	3.9 (3.8 – 4.1)	4.3 (4.1 – 4.5)	4.5 (4.2 – 4.7)	3.5 (3.4 – 3.7)	3.9 (3.7 – 4.1)	4.1 (3.9 – 4.3)
Nigeria	Edo	2.6 (2.2 – 3.0)	2.8 (2.3 – 3.2)	2.8 (2.3 – 3.3)	2.5 (2.1 – 2.8)	2.6 (2.2 – 3.0)	2.7 (2.2 – 3.1)
Ghana	Ashanti	2.5 (1.1 – 4.6)	2.7 (1.2 – 5.1)	2.7 (1.2 – 5.4)	2.3 (1.1 – 4.0)	2.5 (1.1 – 4.5)	2.6 (1.1 – 4.8)
Sierra Leone	Western	2.4 (1.4 – 3.5)	2.5 (1.5 – 3.8)	2.6 (1.5 – 4.0)	2.3 (1.4 – 3.2)	2.4 (1.4 – 3.5)	2.4 (1.4 – 3.7)
Guinea	Kindia	2.3 (2.1 – 2.6)	2.4 (2.1 – 2.8)	2.5 (2.2 – 2.8)	2.2 (1.9 – 2.4)	2.3 (2.0 – 2.6)	2.4 (2.1 – 2.7)
Sierra Leone	Northern	2.2 (2.1 – 2.4)	2.4 (2.2 – 2.5)	2.4 (2.2 – 2.6)	2.1 (2.0 – 2.3)	2.2 (2.0 – 2.4)	2.3 (2.1 – 2.4)
Ghana	Eastern	2.2 (1.1 – 3.7)	2.3 (1.2 – 4.0)	2.4 (1.2 – 4.2)	2.1 (1.1 – 3.3)	2.2 (1.1 – 3.6)	2.2 (1.1 – 3.8)
Guinea	Kankan	2.2 (1.7 – 2.7)	2.3 (1.7 – 2.9)	2.3 (1.7 – 3.0)	2.0 (1.6 – 2.5)	2.1 (1.6 – 2.7)	2.2 (1.7 – 2.8)
Liberia	Grand Bassa	2.2 (0.4 – 7.0)	2.3 (0.4 – 8.5)	2.3 (0.4 – 9.2)	2.0 (0.4 – 5.8)	2.2 (0.4 – 7.4)	2.2 (0.4 – 8.0)
Liberia	Bong	1.8 (0.3 – 7.0)	1.9 (0.3 – 8.5)	2.0 (0.3 – 9.1)	1.7 (0.3 – 5.8)	1.8 (0.3 – 7.3)	1.9 (0.3 – 8.0)
Nigeria	Borno	1.5 (1.0 – 2.2)	1.6 (1.1 – 2.3)	1.6 (1.1 – 2.3)	1.5 (1.0 – 2.0)	1.5 (1.0 – 2.1)	1.5 (1.0 – 2.2)
Guinea	Labe	1.3 (0.8 – 1.9)	1.3 (0.8 – 2.0)	1.3 (0.8 – 2.0)	1.2 (0.8 – 1.8)	1.3 (0.8 – 1.9)	1.3 (0.8 – 1.9)
Nigeria	Ebonyi	1.3 (0.2 – 7.4)	1.3 (0.2 – 9.0)	1.3 (0.2 – 9.8)	1.2 (0.2 – 6.2)	1.2 (0.2 – 7.8)	1.3 (0.2 – 8.5)
Guinea	Boke	1.1 (0.7 – 1.8)	1.2 (0.7 – 1.8)	1.2 (0.7 – 1.9)	1.1 (0.7 – 1.7)	1.1 (0.7 – 1.7)	1.1 (0.7 – 1.8)

463 **Table 3. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is**
464 **6%.** LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in
465 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Country	Admin1	Admin2	Annual Lassa Fever incidence rate (per 1,000)					
			Seroreverted – No Immunity			Seroreverted – Partial Immunity		
			Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)	Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)
Nigeria	Ondo	Ose	12.4 (10.1 – 13.8)	20.7 (14.1 – 28.2)	24.7 (15.9 – 35.2)	9.7 (8.1 – 10.6)	18.0 (12.1 – 25.1)	22.0 (14.1 – 32.0)
Sierra Leone	Southern	Moyamba	11.2 (9.5 – 12.5)	17.6 (13.0 – 22.7)	20.7 (14.7 – 27.6)	8.7 (7.6 – 9.5)	15.0 (11.1 – 19.8)	18.2 (12.7 – 24.7)
Nigeria	Edo	Esan West	9.7 (8.3 – 10.9)	13.2 (10.5 – 16.0)	14.9 (11.4 – 18.5)	7.9 (6.8 – 8.7)	11.3 (9.0 – 13.8)	13.0 (10.0 – 16.2)
Sierra Leone	Northern	Bombali	9.5 (5.8 – 12.2)	13.1 (6.7 – 21.4)	14.9 (7.2 – 25.9)	7.6 (5.0 – 9.3)	11.2 (5.8 – 18.6)	12.9 (6.3 – 23.0)
Sierra Leone	Northern	Koinadugu	9.1 (2.2 – 13.1)	12.2 (2.3 – 27.0)	13.8 (2.4 – 33.6)	7.3 (2.1 – 9.9)	10.4 (2.1 – 23.8)	12.0 (2.2 – 30.6)
Guinea	Nzerekore	Macenta	9.0 (8.2 – 9.6)	11.8 (10.5 – 13.3)	13.2 (11.6 – 15.0)	7.2 (6.7 – 7.7)	10.1 (9.0 – 11.3)	11.5 (10.0 – 13.0)


Mali	Sikasso	Bougouni	7.0 (6.3 – 7.8)	8.3 (7.3 – 9.4)	8.9 (7.8 – 10.2)	6.1 (5.5 – 6.6)	7.3 (6.5 – 8.3)	8.0 (6.9 – 9.1)
Guinea	Faranah	Faranah	6.3 (5.8 – 6.8)	7.4 (6.8 – 8.1)	8.0 (7.2 – 8.8)	5.4 (5.0 – 5.7)	6.5 (5.9 – 7.1)	7.0 (6.4 – 7.7)
Sierra Leone	Southern	Pujehun	6.3 (2.0 – 10.7)	7.4 (2.1 – 15.9)	7.9 (2.1 – 18.4)	5.4 (1.9 – 8.3)	6.5 (2.0 – 13.5)	7.0 (2.1 – 16.1)
Nigeria	Ondo	Owo	5.9 (3.6 – 8.2)	6.7 (3.9 – 10.2)	7.1 (4.0 – 11.2)	5.1 (3.3 – 6.7)	5.9 (3.5 – 8.8)	6.4 (3.6 – 9.8)
Sierra Leone	Eastern	Kailahun	5.6 (3.4 – 7.8)	6.4 (3.7 – 9.6)	6.8 (3.8 – 10.6)	4.8 (3.1 – 6.4)	5.6 (3.4 – 8.3)	6.0 (3.5 – 9.2)
Cote d'Ivoire	Montagnes	Cavally	5.3 (3.7 – 6.9)	6.0 (4.1 – 8.3)	6.4 (4.2 – 9.0)	4.6 (3.4 – 5.8)	5.3 (3.7 – 7.2)	5.7 (3.9 – 7.9)
Sierra Leone	Eastern	Kono	5.1 (0.2 – 12.1)	5.7 (0.2 – 20.9)	6.0 (0.2 – 25.2)	4.5 (0.2 – 0.2)	5.1 (0.2 – 18.0)	5.4 (0.2 – 22.5)
Sierra Leone	Western	Western Rural	5.0 (0.1 – 12.2)	5.7 (0.1 – 21.0)	5.9 (0.1 – 25.5)	4.4 (0.1 – 9.3)	5.0 (0.1 – 18.2)	5.3 (0.1 – 22.4)
Guinea	Kindia	Kindia	4.9 (4.0 – 5.9)	5.5 (4.4 – 6.8)	5.8 (4.5 – 7.2)	4.3 (3.6 – 5.1)	4.9 (3.9 – 5.9)	5.2 (4.1 – 6.4)
Guinea	Nzerekore	Gueckedou	4.6 (4.3 – 5.0)	5.1 (4.7 – 5.6)	5.4 (4.9 – 5.9)	4.1 (3.8 – 4.4)	4.6 (4.3 – 5.0)	4.9 (4.5 – 5.3)
Guinea	Nzerekore	Lola	4.4 (3.8 – 5.1)	4.9 (4.2 – 5.7)	5.1 (4.3 – 6.0)	3.9 (3.5 – 4.4)	4.4 (3.8 – 5.1)	4.6 (3.9 – 5.4)

Cote d'Ivoire	Montagnes	Guemon	4.4 (2.3–6.9)	4.8 (2.4–8.3)	5.1 (2.4–8.9)	3.9 (2.2–5.8)	4.4 (2.2–7.2)	4.6 (2.3–7.9)
Guinea	Nzerekore	Yamou	4.2 (3.7–4.7)	4.6 (4.0–5.3)	4.8 (4.2–5.5)	3.8 (3.4–4.2)	4.2 (3.7–4.7)	4.4 (3.8–4.9)
Sierra Leone	Eastern	Kenema	3.9 (3.7–4.1)	4.3 (4.0–4.5)	4.5 (4.2–4.7)	3.5 (3.4–3.7)	3.9 (3.7–4.1)	4.1 (3.8–4.3)

466

467

468 The age-specific infection histories calculated using the projected and ensemble FOI estimates can also
469 be used to calculate annual LF incidence rates for specific age groups. LF incidence rates decrease with
470 age as the likelihood of a previous infection and at least partial protection from infection and disease
471 increases (Figure 6).
472



473
474 **Figure 6.** Age-group specific annual Lassa Fever (LF) incidence rates per 1,000 in the ten 2nd
475 administrative units with the highest incidence. Incidence calculated using projected FOI estimates from
476 LF case data and estimated reporting probabilities and assuming a seroreversion rate of 6%, seropositive
477 individuals have partial protection from reinfection and disease (RR=0.53), and seroreverted individuals
478 are partially protected (RR=0.36) from reinfections and disease. Boxes represent interquartile range
479 (IQR) and lines the 95% prediction interval.


480 *Interannual variability in incidence*

481 The 1,000 samples from the posterior distribution of the projected FOI estimates incorporate both the
482 uncertainty and the interannual variability in our FOI estimates and the corresponding annual LF
483 incidence rates. Figure (7) provides an example of the variability in LF incidence rates (per 1,000) for the
484 nine highest incidence admin2 units under a scenario where the seroreversion rate is 6%, seroprotected
485 individuals have a relative risk = 0.36 of developing LF if infected, and seroreverted individuals are also
486 partially susceptible to reinfection and disease (relative risk = 0.53). The variation in LF incidence rates is
487 highest for locations where FOI was estimated from LF case data and reporting probabilities only (no
488 serology data) because these estimates incorporate uncertainty in reporting probabilities in addition to
489 interannual variability. Locations where FOI estimates were informed by serology data, such as Macenta
490 and Faranah Districts in Guinea and Sikasso District in Mali, have lower uncertainty. However, even in
491 these locations, the estimated annual LF incidence rate can vary by 10-50% from year-to-year. For
492 example, the narrowest estimated range in annual LF incidence is in Faranah District, Guinea with a
493 median annual incidence of 7.0 per 1,000 (95% CrI: 6.4-7.7), where 95% of years would be expected to
494 be within +/- 10% of the median value. Esan West LGA in Edo State, Nigeria has a median LF incidence
495 rate of 13.0 per 1,000 (95% CrI: 10.0-16.2), with variability of +/- 25% from the median. An example of a
496 location with a high uncertainty and interannual variability is Ose LGA in Ondo State, Nigeria which has a
497 median annual LF incidence rate of 22.0 per 1,000 (95% CrI: 14.1-32.0) with variability of approximately
498 +/- 50%.

499 *Seasonality*


500 Reported LF cases in Nigeria and Liberia, and to a lesser extent in Sierra Leone, show a clear seasonal
501 pattern with a peak in cases in January to March (Figure 8). Liberia also shows a secondary peak later in
502 the year, although this may be part of the January peak in cases. In Sierra Leone, LF cases peak in March,
503 but there appears to be considerable transmission throughout the year.

504
505
506
507
508
509
510



511

512 **Figure 7.** Posterior distribution of annual Lassa fever (LF) case incidence rates in the nine highest admin2
513 units. LF incidence estimates are based on projected FOI estimates from LF case data and reporting
514 probabilities. Results presented are for a scenario with 6% seroreversion rate, partial protection against
515 reinfection and disease in seropositive individuals (relative risk = 0.36), and partial protection against
516 reinfection or disease among seroreverted individuals (RR = 0.53). The red dashed line is the median of
517 the posterior distribution.
518



519
520 **Figure 8.** Seasonality of LF incidence in (A) Nigeria, (B) Liberia, (C) Sierra Leone, and (D) averaged across
521 these three countries. Blue line represents a generalized additive model with a cyclical cubic regression
522 spline fit to the weekly fraction of annual cases (grey represents the 95% confidence interval).

523

524 Discussion

525 Using a modeling framework that incorporated LF serology, case, and death data, we found considerable
526 spatial variation in LASV spillover and LF incidence across West Africa, with the highest incidence rates in
527 areas within Nigeria, Sierra Leone, and Guinea. We also estimate that as few as 0.2% of LASV infections
528 are captured by current surveillance systems. These results represent the most extensive and
529 geographically detailed estimates of LF surveillance and incidence across the entire endemic range in
530 West Africa to date. Our LF incidence estimates were sensitive to assumptions about the duration and
531 strength of infection-induced immunity. LF incidence rates were particularly sensitive to the rate of
532 seroreversion among previously infected individuals because this value affects both susceptibility to
533 reinfection and the interpretation of serology data. Our spatial LF incidence rate estimates, along with
534 the interannual and seasonal variability in these estimates, could be used to target high incidence areas
535 suitable for inclusion in a vaccine trial and estimate expected trial event rates. However, the
536 uncertainties in our LF incidence estimates highlight critical knowledge gaps regarding the number of
537 asymptomatic and mild LASV infections that go undetected and the extent to which these infections
538 provide long-lasting immunity.

539 Our estimates of LF incidence rates indicate that there are few 1st or 2nd level administrative districts
540 where the predicted attack rate would be at least 1% as is desired for vaccine field trials. Our estimates
541 assumed that 20% of LASV infections are symptomatic, as frequently reported. However, if substantially
542 fewer than 20% of infections are captured by active syndromic surveillance, as has initially been
543 reported for the Enable study, then none of these districts would be likely to reach an LF attack rate of
544 1%.¹⁵ Therefore, ensuring sufficient statistical power may require a large increase in the number of
545 individuals enrolled in a field trial. One alternative to increasing the size of the study population would
546 be to use protection against infection as a primary endpoint instead of protection against symptomatic
547 disease. Due to the high number of asymptomatic infections, active monitoring for seroconversion—

548 while more difficult and costly than symptom-based surveillance methods—would increase the number
549 of expected endpoints without increasing the size of the study population. Another option would be to
550 adopt a responsive trial design that employed ring vaccination or a similar strategy to focus study efforts
551 on locations with active transmission. Given the focal nature of LF spillover to humans, and the
552 substantial interannual and seasonal variation in incidence, such a strategy would ensure that areas of
553 active transmission are targeted.^{23,40,46}

554 Trial site selection also needs to account for the baseline seroprevalence in a target population as that
555 will influence the fraction of the population that is susceptible to infection. Locations with high baseline
556 seroprevalence may experience few LF cases even if LASV is actively circulating in the rodent population.
557 However, there is considerable uncertainty about the duration of immunity to LASV, and several studies
558 suggest that seroreversion is relatively common.^{23,24,76} Assumptions about the seroreversion rate had
559 the largest impact on estimated LF incidence among the different immunological scenarios included in
560 our analysis. Without seroreversion, our FOI estimates were too low for the resulting annual LF
561 incidence rates to exceed 10 per 1,000 (1%) anywhere within the study region. Further results from the
562 longitudinal serology samples from the Enable study should help refine our understanding of
563 seroreversion rates and whether they vary by location or age.

564 The level of protection against reinfection and disease among both seropositive and seroreverted
565 individuals also influenced expected LF incidence rates in our model, with higher levels of protection
566 against disease resulting in lower expected incidence rates. The different scenarios explored in our
567 model could be leveraged to select the most plausible scenario for estimating event rates in a particular
568 site and target population. This model can also be used to explore how LF incidence rates vary by both
569 age and serostatus under different assumptions regarding how serostatus affects susceptibility to
570 (re-)infection and disease, which can help to inform selection of a target population and trial size
571 calculations. Results from the Enable study will also help refine future model scenarios regarding the

572 role of immunity and serostatus, as the study will report relative LF incidence rates among individuals
573 who were seropositive or seronegative at baseline (or in the previous sampling period) and may also be
574 able to capture the reinfection and LF incidence rates among individuals who serorevert over the course
575 of the study.

576 Our model projections represent the most extensive and geographically detailed estimates of LF
577 surveillance and incidence across the entire endemic range in West Africa to date. Previous modeling
578 studies have generated fine-scale maps of the likely distribution of LASV, but have not estimated LF
579 incidence rates or seroprevalence in the human population.^{26,28,51} Basinski et al. (2021) modeled LASV
580 risk in rodents and then fit a regression model of this risk measure against historical seroprevalence data
581 to generate fine-scale estimates of LASV seroprevalence in the human population.²⁵ However, their
582 study did not incorporate LF incidence data or account for certain epidemiological features of LF in
583 generating these estimates. Our projected FOI estimates and modeled annual LF incidence rates indicate
584 that Sierra Leone, southern Guinea near the border with Sierra Leone and Liberia, and a few high
585 incidence regions within Nigeria would likely yield the highest LF case incidence rates during a vaccine
586 trial. Comparisons of our estimates at the 1st and 2nd administrative levels show that there is
587 considerable spatial heterogeneity among different admin2s within the same 1st administrative unit
588 (particularly in Nigeria, Guinea, and Mali), and therefore predictions from the 2nd administrative level
589 are likely to be more useful for site selection.

590 The 2nd administrative level FOI estimates that were projected from LF case data and reporting
591 probabilities appear to be more accurate than the FOI estimates from our ensemble model that used
592 spatial covariates to improve model predictions in areas lacking data, particularly in areas that are
593 projected to have the highest incidence. The ensemble model smoothed over the spatial heterogeneity
594 in FOI to an extent that lowered the incidence rate in some regions with a high number of reported
595 cases and deaths, particularly in Edo and Ondo states in Nigeria. Therefore, at present, the projected FOI

596 estimates likely provide more reliable estimates for field trial site selection than the estimates from the
597 ensemble model. Further model refinements, including model selection techniques to determine the
598 most influential spatial covariates, and further model validation using serology data from the literature
599 and forthcoming Enable results could improve the ensemble model predictions. However, regression
600 analyses and ensemble modeling methods are most useful for predicting incidence where data is sparse
601 and the relationship between the response variable (incidence) and the explanatory variables is strong.
602 There is still a lot of uncertainty about what conditions distinguish areas with high LASV spillover rates
603 from areas with similar environmental conditions and where *Mastomys spp.* are present, but spillover is
604 rare or nonexistent. Hopefully additional field studies and serological surveys will help explain these
605 discrepancies, but at present we lack the ability to predict the occurrence of LF at a fine spatial scale
606 outside of the well-documented hotspots of transmission. In the absence of this ability, our admin2
607 incidence estimates could help identify broader regions to target for vaccine trials, and baseline serology
608 surveys can be conducted at the local level to confirm LASV spillover in the area. In particular, evidence
609 of past infection in younger children would indicate recent transmission.

610 Our modeling framework did incorporate estimation of country specific LF case and death reporting
611 probabilities, but it also seems unlikely that areas within the study region that haven't reported any LF
612 cases or deaths have as high a burden of LF as the known hotspots in Nigeria, Sierra Leone, Guinea, and
613 Liberia. The burden of LF outside of the known hotspots is an important outstanding question, but it is
614 likely that observed spatial patterns of reported LF cases and deaths reflect at least some important
615 differences in the spatial distribution of the disease. Although mild and moderate LF cases are difficult to
616 distinguish from other febrile illnesses such as malaria, severe LF cases requiring hospitalization have
617 been associated with nosocomial outbreaks in Nigeria, Sierra Leone, and Liberia, but not in other areas
618 West Africa.⁷⁷⁻⁷⁹ A seroprevalence study in multiple locations within Ghana, and preliminary
619 seroprevalence results from the Enable site in Benin also suggest that transmission is lower in these

620 countries than it is in the known hotspots for transmission.⁵¹ However, high seroprevalence were
621 recently observed in southern Mali, suggesting that there may be undocumented areas of LF incidence
622 outside of the historical hotspots.^{80,81}

623 *Model limitations*

624 Despite recent efforts to prioritize the study of LF, there are still many unknowns, which limit the
625 predictive power of our model. LF incidence rates vary significantly based on many confluent factors,
626 and the limited number of longitudinal and broad scale studies makes it difficult to draw significant
627 conclusions about the risk of LF in a particular time and place. Our model does not account for non-
628 epidemiological considerations that may influence site selection, such as the strength of the existing
629 local or national health infrastructure system, political stability, or cultural barriers to trial
630 implementation. However, the model results can be used to rank potential trial sites by expected LF
631 incidence rates and seroprevalence (e.g., expected serostatus by age group), and then other factors can
632 be used to select appropriate trial sites from locations with suitable characteristics.

633 The current model also cannot estimate the geographical variation in expected LF incidence rates within
634 a given 2nd administrative area. Past serology studies in Guinea and Sierra Leone, and preliminary results
635 from the Enable study, show that seroprevalence rates can vary significantly from village to village
636 within the same state or district.^{23,40,46} However, the identification of risk factors associated with small-
637 scale variations in seroprevalence, infection attack rates, or LF incidence have been inconsistent, limiting
638 our ability to predict high incidence areas within a given administrative region. The Enable study will
639 provide some additional context on this finer-scale heterogeneity in attack rates and incidence due to
640 the large sample size and the relatively high number of villages sampled. However, the targeted criteria
641 used for site selection may limit our ability to extrapolate the study results beyond these study sites.
642 Variation in our estimated LF incidence rates for a given location results from a combination of

643 parameter uncertainty and interannual variability in reported LF cases and deaths. Longitudinal
644 serological or incidence data was insufficient to explicitly estimate interannual variability across the
645 study area.

646 *Conclusions*

647 Our modeling framework enabled us to leverage multiple data sources to estimate LF incidence at the
648 2nd administrative level across West Africa. Expected incidence varied considerably and showed marked
649 geographic variation across spatial scales. Although an ensemble of regression models showed
650 moderate success at predicted incidence based on environmental and socioeconomic data, it tended to
651 underestimate incidence in high-risk regions, which are the most relevant for disease control and
652 vaccine trial planning. Our work highlights the importance of ecological and immunological factors and
653 underscores large uncertainties in our understanding of LF epidemiology. Our findings emphasize the
654 need for more prospective data (e.g., the Enable study), particularly regarding the fraction of infections
655 that are detectable by syndromic surveillance and the duration of infection-induced immunity. At the
656 scales considered, very few locations in West Africa are predicted to experience LF incidence at the
657 levels needed to conduct a vaccine efficacy trial (annual incidence of at least 10 per 1000). Designs
658 would need to accommodate low disease incidence (e.g., preparatory observational studies and active
659 monitoring for asymptomatic infections) or look to prospectively enrich the trial population with at risk
660 individuals (e.g., ring vaccination). Our modeling framework is designed to be updated iteratively with
661 future serological survey data and LF surveillance data. Our estimated incidence rates are intended to
662 assist with trial site selection, sample size calculations, and the decisions regarding the appropriate
663 target population and primary endpoint.

664 **Acknowledgements**

665 The authors thank CEPI for insights into current planning considerations for Lassa fever vaccine trials and
666 an overview of the preliminary results from the ENABLE study. We thank Melissa Wynn, Carrie Mills,
667 Kevin Sprurgers, and Lovelyn Charles at Emergent Biosolutions for help with coordinating research
668 efforts.

669 **Author Contributions**

670 Conceptualization: SMM, NED, STS

671 Data Curation: SMM, ER, SMG

672 Formal Analysis: SMM

673 Funding Acquisition: STS

674 Investigation: SMM

675 Methodology: SMM, NED, STS

676 Project Administration: SMG, STS

677 Resources: SMM

678 Software Programming: SMM

679 Supervision: STS

680 Validation: SMM

681 Visualization: SMM, ER

682 Writing – Original Draft Preparation: SMM, ER

683 Writing – Review & Editing: SMM, ER, SMG, NED, STS

684

685 **Supporting Information**

686 **S1 Appendix**

687 **Model Details**

688 **1. Estimating the Force of Infection from Serology Data**

689 For administrative units with serology data binned by age group, we calculated the likelihood of the FOI
690 (λ) based on the number of individuals between ages a_1 and a_2 (the upper and lower bounds of the age
691 group) who tested positive, $P(a_{1:2})$, out of the total number sampled, $T(a_{1:2})$. The likelihood was
692 calculated for each age between a_1 and a_2 assuming a binomial distribution, $P(a_{1:2}) \sim$
693 $Binomial(T(a_{1:2}), p(a))$ where $p(a)$ is the probability that an individual was seropositive as determined by
694 equation (2). We then took a weighted average of the likelihood for each age group, with the weighting
695 determined by the proportion of the population in that administrative unit in each age within the age
696 group. We calculated the likelihood of the overall FOI (λ_i) in administrative unit i by summing the logs of
697 the binomial probabilities of $P_i(a_{1:2})$ across all age groups in a given seroprevalence dataset. The
698 likelihood of a given FOI (λ_i) for each administrative unit i was calculated across a range of values
699 between 10^{-6} and 10^1 . We then fit a gamma distribution using the *optim* function in R to estimate shape
700 and scale parameters representing the mean and variance in FOI (λ_i), and these parameters were used
701 as inputs to the subsequent steps in the modeling framework.

702 **2. Estimating Country-specific Reporting Fractions**

703 For each administrative unit where the FOI was estimated from serological data in the previous step, we
704 estimated the fraction of LF infections from 2010-2023 that went unreported based on the discrepancy
705 between reported LF cases and deaths and the number of infections predicted by the FOI estimates
706 from those sites under the three different seroreversion scenarios. We assume that all individuals within
707 an administrative unit are at risk of LASV infection and that each individual has the potential to fall into

708 one of three categories during the study period: an observed LF case, an observed LF death, or
709 unobserved. The unobserved category includes both individuals who were not infected and individuals
710 who had an unobserved LASV infection (either because it was an asymptomatic infection or was an LF
711 case/death that was not reported). We therefore modeled the distribution of person-years from 2010-
712 2023 across these three categories: observed deaths, D_i ; observed cases, C_i ; and the total unobserved
713 person-years, N_i . For administrative unit i , the total unobserved person-years, N_i , is calculated as $N_i = Y_i -$
714 $C_i - D_i$, where $Y_i = \sum P_{op_i}$ is the sum of the annual population sizes from 2010-2023. The probability that a
715 person of age a in year y would die from LF and be reported as such was,

$$716 \quad \Pr(\text{reported death}, a | \lambda_i, U_i, \rho_D, \pi) = (1 - p(a)) \frac{\lambda}{\lambda + \pi} (1 - e^{-(\lambda + \pi)}) (1 - U_i) \rho_D, \quad (A1)$$

717 where U_i is the proportion of infections that are unobserved in location i and ρ_D is the proportion of
718 observed infections that result in death. Equation A1 represents the probability that an individual was
719 susceptible at time y , and subsequently becomes infected in year y (based on the FOI, λ) and
720 experienced an infection that was both observed and resulted in death. The probability of a reported
721 case was the same as equation (A1) but with ρ_D replaced by $1 - \rho_D$. The probability of an unobserved
722 person-year, $\Pr(\text{unreported person-year}, a | \lambda_i, U_i, \pi)$, takes into account the multiple ways in which
723 a person-year would not result in a reported death or case, including currently being immune due to a
724 past infection, by not being infected during the study time period from 2010-2023, or by being infected
725 in year y but not being reported. From $\Pr(\text{reported death})$, $\Pr(\text{reported case})$, and $\Pr(\text{unreported person-}$
726 $\text{year})$ we calculate the probability of D_i , C_i , and N_i among Y_i total person-years, $\Pr(D_i, C_i, N_i | \lambda_i, U_i, \rho_D)$,
727 using a multinomial distribution. Given estimates of λ_i from step 1, we used this distribution to estimate
728 the parameter U_i for each i , and country-specific values for ρ_D . The log likelihood of U_i and ρ_D was
729 calculated by summing the logs of the probabilities from $\Pr(D_i, C_i, N_i | \lambda_i, U_i, \rho_D)$ assuming
730 noninformative priors between 0 and 1 for all U_i and a beta-distributed prior for ρ_D with shape

731 parameters 2.05 and 6.85. The posterior distributions of the parameters were then sampled using the
732 BayesianTools package in R.

733 To extrapolate reporting fractions beyond the few administrative units with both serological and
734 case/death data, we fit a Dirichlet distribution to the posterior predictions of the proportions of
735 infections that result in a reported death, a reported case, or an unreported infection. For each draw j
736 from the posterior, the proportions of reported deaths, reported cases, and unreported infections were
737 calculated respectively as $(1 - \bar{U}_j)\rho_{D,j}$, $(1 - \rho_{D,j})$, and \bar{U}_j ; with \bar{U}_j , $\rho_{D,j}$ representing the country-
738 specific averages across all sites i within a country for each draw j from the posterior distribution. The
739 corresponding Dirichlet parameters associated with reported cases, reported deaths, and unreported
740 infections were α_D , α_C , and α_U . We estimated these Dirichlet parameters by maximum likelihood using
741 the *optim* function in R, treating posterior predictions of the proportion of infections that result in a
742 reported death, a reported case, or an unreported infection as data points drawn from the Dirichlet
743 distribution being fitted.

744 **3. Estimating LASV spillover rates**

745 For each administrative unit we next estimated the total number of annual infections, I_i , based on the
746 reported LF cases and deaths from 2010-2023 along with the estimated reporting probabilities from the
747 previous step. The likelihood of a given number infections, I_i , in administrative unit i was calculated using
748 the Dirichlet-multinomial probability of obtaining the reported deaths, D_i , and reported cases, C_i , and $I_i -$
749 $D_i - C_i$ unobserved infections following I_i draws of those categories according to Dirichlet-distributed
750 probabilities with parameters α_D , α_C , and α_U from step 2:

$$751 \quad L(I_i | C_i, D_i, \alpha_D, \alpha_C, \alpha_U) = \Pr(D_i, C_i, I_i - D_i - C_i | I_i, \alpha_D, \alpha_C, \alpha_U).$$

752 We normalized the likelihoods from this equation across all values of I_i to obtain posterior probabilities
753 of each I_i , which we used to obtain a set of posterior samples of I_i for each admin1 and admin2 unit.

754 **4. Projecting the Force of Infection from estimated LASV spillover rates**

755 For each administrative unit where LASV spillover infections were estimated from LF case/death data,
756 we projected the underlying FOI that would correspond to the estimated infection rate. The projected
757 FOI_{*i*} for each administrative unit *i* was obtained by minimizing the difference between the number of
758 infections, *I_i*, estimated in the previous step and the expected number of infections arising from a given
759 FOI in the reverse catalytic model from equation (2) using the *optim* function in R. This resulted in a
760 posterior distribution of FOI_{*i*} for each admin1 and admin2 unit.

761 **5. Estimation of Population-level Infection Histories**

762 The FOI projections generated from serology and case data in step 4 were next used to simulate
763 population-level infection histories for each admin1 and admin2 unit. For the FOI projections, we drew
764 1000 samples for each administrative unit from the posterior distribution using the estimated shape and
765 scale parameters from the gamma distribution estimated in step 1. For each value FOI_{*i,j*}, (where *j*=1000
766 is the sample set) we computed the proportion of the population in administrative unit *i* that had been
767 infected by age *a* using the catalytic model in equation (1), and the proportion of the population
768 seropositive at age *a* using the reverse catalytic model in equation (2).

769 **6. Estimating LASV Infection and LF Attack Rates**

770 The population-level infection histories and FOI estimates were then used to compute the expected
771 number of infections in each administrative unit *i*. We examined several different scenarios regarding
772 the risk of seropositive or seroreverted individuals becoming reinfected and developing LF as described
773 in the *Methods* section of the main text. The expected annual number of infections in administrative
774 unit *i* were calculated from the FOI_{*i*} using the reverse catalytic model for each of the 18 different
775 scenarios at both the admin1 and admin2 levels. The number of infections was multiplied by the

776 symptomatic probability (20%) to obtain an estimate of the expected number of LF cases in each
777 administrative unit.

778 *Modeling the Force of Infection from Covariate Data*

779 The estimation of LASV spillover rates and the projection of the FOI from these spillover rates was
780 performed for all admin1 and admin2 administrative units within the study region. However, LF cases or
781 deaths have been reported in <50% of administrative units within the region (Figure 1), and infection
782 estimates for these administrative units without any reporting are contingent on our estimated
783 underreporting probabilities. In addition, there is also a large degree of uncertainty in the true spillover
784 rate in administrative units that have reported only a small number of LF cases due to the large
785 proportion of asymptomatic infections and low reporting probabilities. Therefore, we used several
786 statistical models to explore the relationships between our FOI_i estimates from step 4 and several key
787 spatial covariates (Supplemental Table S2). These models were fit to the projected FOI_i estimates from
788 administrative units with either serology data or reported LF case/death data (N=77 of 164 admin1s,
789 N=372 of 1375 admin2s). The fitted models were then used to predict FOI in the administrative units
790 with no serology or case data. Given that we have a relatively small dataset and high uncertainty in our
791 projected FOI estimates, we considered eight different models, as well as a null model with a single FOI
792 estimated across all administrative units. The first two models were linear regression models with or
793 without two-way interaction terms between covariates. We also considered four different Gaussian
794 Markov random field (GMRF) models: two with no covariates and two with linear effects of the
795 covariates. GMRF models use a minimum mean squared error linear prediction with spatial covariance
796 for spatial prediction or interpolation⁸². The GMRF models with or without linear effects for the
797 covariates were run at two spatial resolutions: a low resolution (k=10 free parameters for admin1 and
798 k=25 for admin2) or high resolution (k=40 for admin1 and k=100 for admin2). The seventh model was a

799 random forest model implemented in R with the *randomForest* package. The eighth, and final, model
800 was a boosted regression model implemented in R with the *gbm* package.

801 For each of the models we took 1000 samples from the posterior distributions of FOI_i from step 4 and
802 regressed \log_{10} FOI against the covariates (where applicable), resulting in 1000 separate fits per model.
803 The predicted values for both the fitted and unfitted administrative units from each model were then
804 treated as point estimates to construct a set of 1000 posterior samples of FOI_i for each administrative
805 unit and each model.

806 *Ensemble model*

807 For each seroreversion scenario, we generated an ensemble model projection of FOI in each admin1 or
808 admin2 using a form of stacked generalization⁸³. Stacked generalization treats the eight statistical
809 models as being at one level and uses the first-level models to generate a higher-order model that
810 weights the predictions of the first-level models into its own prediction. The performance of each first-
811 level model was assessed using a ten-fold cross-validation technique, with 90% of the data partitioned
812 into the training set to fit the model, and the remaining 10% withheld for model validation. This process
813 was performed ten times, with a different 10% of the dataset withheld for validation each time. Model
814 performance was then assessed based on the model predictions on the withheld data and ensemble
815 weights for each model were calculated based on relative model performance.

816

817

818 **S1 Results**

819 **1. Statistical and ensemble model results**

820 At the admin1 level, the most important covariates in the random forest model were longitude, travel
821 time to the nearest urban center, and the Healthcare access and quality index (HAQ) (Table S3). The
822 most influential covariates in the boosted regression model were longitude, travel time to the nearest
823 urban center, and the estimated probability of LASV presence in *Mastomys natalensis* (Table S4). At the
824 admin2 level, the most important covariates in the random forest model were longitude, HAQ, and the
825 2nd precipitation PC (Table S5). The covariates with the largest t-values in the linear model with
826 interactions were longitude, the fraction of forest loss since 2000, and percentage of tropical habitat
827 (Table S6).

828 The performance of the model predictions on data held out of the regression for model validation was
829 much lower for the 1st administrative level, with random forest providing the best fit to the testing data
830 ($r^2=0.32$), suggesting that the models are overfitting to the training dataset (Figure S5). The cross-
831 validation performance of most regression models was better at the 2nd administrative unit, with the
832 random forest model providing the best fit ($r^2=0.76$), and the boosted regression and GMRF models with
833 and without covariates all maintaining an $r^2>0.70$ (Figure S6). The low ratio of data points per covariate
834 at the admin1 level may explain the poor cross-validation performance relative to the admin2 level
835 (N=77 for admin1 vs. N=372 for admin2).

836 *Ensemble model*

837 Our ensemble model consisted of a weighted combination of the FOI predictions of each individual
838 statistical regression model, along with a noise term. Each model weight was calculated based on its
839 negative marginal log likelihood in ten-fold cross-validation. Assuming a 6% seroreversion rate, the
840 highest model weight for the admin1 ensemble model was the random forest model (43.7%), followed

841 by the boosted regression model (35.1%), the high resolution GMRF with covariates (9.9%), the high
842 resolution GMRF without covariates (6.0%), and the low resolution GMRF with covariates (5.2%). For the
843 admin2 ensemble model the model weights of at least 5% in decreasing order were: the random forest
844 model (46.3%), the high resolution GMRF with covariates (15.1%), the low resolution GMRF without
845 covariates (13.7%), the high resolution GMRF without covariates (11.5%) and the boosted regression
846 model (5.8%).

847 Ensemble model estimates of FOI at the 1st administrative level show a similar spatial pattern and
848 magnitude to the projected FOI estimates (Figure 4A), with predicted high FOI areas in Sierra Leone,
849 Guinea, and southern Nigeria (Figure S9A). However, there are admin1 units that did not report any LF
850 cases or deaths from 2010-2023, and therefore had low projected FOI values, but are predicted by the
851 ensemble model to have high FOI values. The ensemble model FOI estimates at the 2nd administrative
852 unit (Figure S9B) show much less spatial heterogeneity than the projected FOI estimates from LF case
853 data and reporting probabilities (Figure 4B). This largely results from the higher weighting of the GMRF
854 models, which include spatial smoothing (45.7% combined among the four GMRF models). This spatial
855 smoothing results in lower FOI estimates in the few projected Nigerian hotspots, and lower within- and
856 among-country variation in FOI estimates overall.

857

858

1. Table S1. Papers selected for in-depth literature review.

Title	Author	Study topic	Publication date	Study date	Country	Sample size	Pop details	IgG pos	IgM pos	PCR pos	Symp. rate	Seasonality (Y/N)	Rainfall (Y/N)	Vegetation (Y/N)	Risk factors
<u>Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria</u>	Akhmetzhanov et al ³¹	Environment / seasonality	2019		Nigeria			na	na	na	na	na	Y	na	LF seasonality not associated w number of infected rodents, but yes w rainfall
<u>A seasonal model to assess intervention strategies for preventing periodic recurrence of Lassa fever</u>	Barua et al ⁸⁴	Environment / seasonality	2021	2018 - 2020	Nigeria		Edo and Ondo states	na	na	na	na	na	na	na	
<u>Risk Maps of Lassa Fever in West Africa</u>	Fichet-Calvet, Rogers ⁵¹	Environment / seasonality	2009	1963 - 2007	All published Lassa cases			na	na	na	na	na	Y	N	Rainfall, not vegetation

<u>Mapping the zoonotic niche of Lassa fever in Africa</u>	Mylne et al ⁵²	Environment /seasonality	2015	1963 - 2014	All published Lassa cases			na	na	na	na	na	Y	Y	Vegetation, land surface temp, rat dist, elevation, potential evapotranspiration
<u>Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria</u>	Redding et al ⁵	Environment / seasonality	2021	2012 - 2019	Nigeria			na	na	na	na	na	Y	Y	Low precipitation, vegetation decline
<u>Annual Incidence of Lassa Virus Infection in Southern Mali</u>	Safronetz et al ⁷	Incidence	2017	2015 - 2016	Mali	532	Three villages in southern Mali (Soromba, Bamba, and Bazana); follow-up to 2015 study from Sogoba et al	na	na	na	na	na	na	na	No significant risk factors

<u>Lassa Virus</u> <u>Circulation in</u> <u>Small Mammal</u> <u>Populations in Bo</u> <u>District, Sierra</u> <u>Leone</u>	Bangura et al ⁵⁸	Rodent epi	2021	2014 - 2016	Sierra Leone	1490	1490 small mammals in 6 villages in Bo District; 357 M natalensis, 345 P rsotratus, 261 R rattus	8.1%	na	1%	na	Y	na	na	Significant seasonal variation, 40% at the start of rainy season; trapping success highest in farming communities, most trapping inside houses
<u>Geographic</u> <u>Distribution and</u> <u>Genetic</u> <u>Characterization</u> <u>of Lassa Virus in</u> <u>Sub-Saharan Mali</u>	Safronetz et al ²⁹	Rodent epi	2013	2007 - 2012	Mali	511	Villages across Mali; 715 total, 511 M nat	6.8%	na	8%	na	na	na	na	
<u>Lassa Serology in</u> <u>Natural</u> <u>Populations of</u> <u>Rodents and</u> <u>Horizontal</u> <u>Transmission</u>	Fichet-Calvet et al ⁵⁵	Rodent epi	2014	2002 - 2004	Guinea	1551	17 villages in different vegetation zones	18.0 %	na	10%	na	N	na	na	No seasonality, no sex

<u>Fluctuation of Abundance and Lassa Virus Prevalence in Mastomys natalensis in Guinea, West Africa</u>	Fichet-Calvet et al ⁶⁵	Rodent epi	2007	2003 - 2005	Guinea	553	Northern Guinea; 1123 total animals, 553 M natalensis	na	na	15%	na	Y	na	na	Highest in rainy season
<u>Sequence Variability and Geographic Distribution of Lassa Virus, Sierra Leone</u>	Leski et al ⁸⁵	Rodent epi	2015	2009	Sierra Leone	681	199 M natalensis at 13 locations in 3 districts in the south and east of SL	na	na	18%	na	na	na	na	
<u>Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria</u>	Agbonlahor et al ⁵⁹	Rodent epi	2017	2015 - 2016	Nigeria	1500	Edo (North: 100, South: 200, Central: 200) Delta (N: 200, C: 200, S: 100) and Bayelsa (W: 200, C:	na	na	11-87%	na	na	na	na	

							200, E: 100) states								
<u>Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria</u>	Happi et al ⁸⁶	Rodent epi	2022	2018 - 2020	Nigeria	942	Ondo and Ebonyi; 942 includes not just M natalensis (did not provide number)	na	na	41.2-72.1 %	na	na	na	na	
<u>Lassa Fever in Guinea: II. Distribution and Prevalence of Lassa Virus Infection in Small Mammals</u>	Demby et al ⁵⁴	Rodent epi	2001	1996 - 1997	Guinea	884	444 households; 1616 total rodents, 884 Mastomys	11.0 %	na	na	na	Y	na	Y	Relates animal positivity w humans by region/forestation
<u>Widespread arenavirus occurrence and seroprevalence in</u>	Olayemi et al ⁵⁶	Rodent epi	2018	2011 - 2015	Nigeria	906	M natalensis in 11 sites in Nigeria	1-52%	na	na	na	N	na	na	Didn't find evidence of seasonality but

<u>small mammals, Nigeria</u>															also small sample size
<u>Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades</u>	Klitting et al ⁸⁷	Rodent epi	2022		Africa			na	na	na	na	na			
<u>Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali</u>	Sogoba et al ⁴⁷	Serology	2016	2015	Mali	600	Three villages in southern Mali (Soromba, Bamba, and Bazana)	33.2 %	0.7%	na	na	na	na	na	Higher age, no sex
<u>Lassa fever in Nigeria: Insights into seroprevalence and risk factors in rural Edo State: A pilot study</u>	Tobin et al ⁴⁸	Serology	2015		Nigeria	177	Edo, Esan West LGA; 50 households, 177 individuals	58.2 %	1.1%	na	na	na	na	na	No assn sex, education, social class (IgG); lower in age < 20 and unmarried

<u>Seroepidemiologic</u> <u>al study reveals</u> <u>regional co-</u> <u>occurrence of</u> <u>Lassa- and</u> <u>Hantavirus</u> <u>antibodies in</u> <u>Upper Guinea,</u> <u>West Africa</u>	Klempa et al ⁴¹	Serology	2012	2004	Guinea	253		40.3%	2.8%	0%	na	na	na	na	No assn sex or month of collection (May vs Oct), lower seroprevalence in youngest and oldest
<u>Space-Time</u> <u>Trends in Lassa</u> <u>Fever in Sierra</u> <u>Leone by ELISA</u> <u>Serostatus, 2012–</u> <u>2019</u>	Shaffer et al ⁸	Serology	2021	2012 - 2019	Sierra Leone	3277	tested at KGH LF Lab	33.6%	31.5%	na	na	na	Y	Y	Temp, precipitation, and presence of pastures main factors for ecological suitability in M natalensi; <20% pastureland and temps < 25 C not suitable
<u>Rodent-borne</u> <u>infections in rural</u>	Nimo-Paintsil et al ⁵⁰	Serology	2019		Ghana	657	7 northern villages (savannah	5.2%	na	na	na	N	na	Y	No seasonality, no sex, no age

<u>Ghanaian farming communities</u>							woodland) and 3 transition zone villages								
<u>Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study</u>	Kerneis et al ⁴⁰	Serology	2009	2000	Guinea	977	Gueckedou, Lola, and Yomou prefectures	11.3 %	na	na	na	na	na	na	Slightly higher IgG in rural vs urban; no association with any rat interaction behaviors
<u>Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea</u>	Longet et al ⁴²	Serology	2023	2016 - 2017	Guinea	702		11-59.6 %	na	na	na	na	na	Y	No assn with sex, age only in coastal, yes environmental fragmentation
<u>Lassa virus activity in Guinea: distribution of human antiviral antibody defined</u>	Lukashevich et al ⁴³	Serology	1993		Guinea	3100	3100 households, 27 villages; split between	4-55%	na	na	na	na	na	Y	High prev in secondary forest areas and savannah, lower in mountains and

<u>using enzyme-linked immunosorbent assay with recombinant antigen</u>							four biome regions								coast, no age or sex differences
<u>Lassa Fever in the Eastern Province of Sierra Leone, 1970–1972</u>	Fraser et al ⁴⁴	Serology	1974	1970 - 1972	Sierra Leone			6.0%	na	na	na	na	na	na	
<u>Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study</u>	Grant et al ⁴⁶	Serology	2023	2015 - 2018	Sierra Leone	10642	Sierra Leone, “endemic”, “emerging”, and “non endemic” regions	10.6-20.1 %	na	na	na	na	na	Y	Poor housing construction; proximity to bushland, forested areas, and refuse; male; work in transport, healthcare, farming, and mining; reverse assn with age; several house quality factors

<u>Serosurveillance of viral pathogens circulating in West Africa</u>	O'Hearn et al ⁴⁵	Serology	2016	2007 - 2014	Sierra Leone	675	Serum samples submitted to Lassa Diag Lab at Kenema Gov Hospital	50.2 %	na	na	na	na	na	na	
<u>A Prospective Study of the Epidemiology and Ecology of Lassa Fever</u>	McCormick et al ²³	Serology	1987		Sierra Leone	5213	5213 individuals, 15 village	8-52%	na	na	na	na	na	na	Age 20-50 IgG peaks, mining village > agricultural village, 'disheveled' homes, food left out, etc
<u>Lassa Fever, Nigeria, 2003 and 2004</u>	Aremu Omilabu et al ⁸⁸	Symptomatic rate	2005	2003 - 2004	Nigeria	50	Specialist Teaching Hospital in Irrua -- 31 febrile, 17 healthy contacts, 12	na	na	na	67%	na	na	na	

							healthy hospital staff								
<u>A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018</u>	Dan-Nwafor et al ⁸⁹	Symptomatic rate	2019	2018	Nigeria	28	17 asymptomatic contacts, 10 symptomatic cases	na	na	na	67%				
<u>Immunological screening of Lassa Virus among Health workers and Contact of patients of Lassa fever in Ondo State</u>	Ojonugwa Shaibu et al ⁹⁰	Symptomatic rate	2021	2018 - 2019	Nigeria	233	Ondo state, Owo and Ose LGA; 102 HCW, 109 case contacts, 22 recovered cases	44.6 %	8.6%	0%	na	na	na	na	

Table S2. Population-level covariates with a potential association with LF occurrence.

Covariate	Reference
Population (2020)	63
Monthly precipitation (12) – Reduced by PCA	91
Monthly mean temperature (12) – Reduced by PCA	91
Monthly NDVI (12) – Reduced by PCA	92
Elevation	93
Longitude	
Latitude	
Healthcare access and quality index (HAQ)	67
Percent urban population	94
Mean travel time to nearest urban center	66
Percent frontier land cover (e.g., forest edge)	95
Percent tropical habitat	68
Percent agricultural land	69
Fraction forest loss since 2000	70
Probability of <i>Mastomys spp</i> presence	25
Probability of LASV presence in <i>Mastomys spp</i>	25
Presence of improved housing	71

International Wealth Index	72
Occurrence of bushmeat hunting	73
Malaria parasite prevalence	96

Table S3. Variable importance in the Random Forest model at the 1st administrative level. Variable importance calculated with median projected FOI as the response variable.

Covariate	Variable Importance
Longitude	8.1
Mean travel time to nearest urban center	5.9
Healthcare access and quality index (HAQ)	3.4
Latitude	2.3
Probability of LASV presence in <i>Mastomys spp</i>	2.3
Fraction forest loss since 2000	2.3
Probability of <i>Mastomys spp</i> presence	2.1
Temperature – first principal component	1.9
Temperature – second principal component	1.9
NDVI – second principal component	1.7
Occurrence of bushmeat hunting	1.5
Precipitation – first principal component	1.5
Elevation	1.5
NDVI – first principal component	1.5
Temperature – third principal component	1.4
Presence of improved housing	1.3
Precipitation – second principal component	1.2
Malaria prevalence	1.2

Percent frontier land cover	1.2
Precipitation – third principal component	1.1
Percent agricultural land	0.9
Percent tropical habitat	0.3

Table S4. Variable importance in the Boosted regression tree model at the 1st administrative level.

Variable importance calculated with median projected FOI as the response variable.

Covariate	Variable Importance
Longitude	43.7
Mean travel time to nearest urban center	31.2
Probability of LASV presence in <i>Mastomys spp</i>	19.9
Probability of <i>Mastomys spp</i> presence	11.0
Latitude	9.8
Temperature – second principal component	7.9
Fraction forest loss since 2000	7.9
Percent frontier land cover	7.0
Malaria prevalence	6.2
Presence of improved housing	6.1
Temperature – first principal component	6.1
Healthcare access and quality index (HAQ)	4.8
Elevation	4.8
Percent agricultural land	4.2
NDVI – second principal component	3.6
Temperature – third principal component	3.6
Precipitation – first principal component	3.5
Precipitation – second principal component	3.0

Occurrence of bushmeat hunting	1.9
Precipitation – third principal component	1.8
NDVI – first principal component	1.2
Percent tropical habitat	0.0

Table S5. Variable importance in the Random Forest model at the 2nd administrative level. Variable importance calculated with median projected FOI as the response variable.

Covariate	Variable Importance
Longitude	91.3
Healthcare access and quality index (HAQ)	53.0
Precipitation – second principal component	20.6
Fraction forest loss since 2000	14.7
Mean travel time to nearest urban center	11.7
NDVI – first principal component	10.4
Probability of LASV presence in <i>Mastomys spp</i>	8.8
Occurrence of bushmeat hunting	8.0
Precipitation – third principal component	6.7
Malaria prevalence	5.9
Probability of <i>Mastomys spp</i> presence	5.5
Temperature – second principal component	5.2
Precipitation – first principal component	4.7
Temperature – third principal component	4.6
Presence of improved housing	3.9
NDVI – second principal component	3.7
Latitude	3.7
Elevation	3.7

Temperature – first principal component	3.6
Percent agricultural land	2.7
Percent frontier land cover	2.1
Percent tropical habitat	0.6

Table S6. Coefficient estimates and t-values for the linear model with interaction terms at the 2nd administrative level with median projected FOI as the response variable.

Covariate	Estimate	SE	T value	P-value
Longitude	-1.38	0.43	-3.21	0.0015
Fraction forest loss since 2000	0.23	0.07	3.07	0.0024
Percent tropical habitat	-0.12	0.05	-2.64	0.0088
Percent frontier land cover	-0.10	0.05	-2.23	0.0265
Latitude	-2.25	1.03	-2.19	0.0297
Presence of improved housing	-0.23	0.12	-1.91	0.0575
Temperature – second principal component	-0.50	0.26	-1.90	0.0588
Temperature – first principal component	0.39	0.23	1.73	0.0843
Mean travel time to nearest urban center	0.48	0.30	1.62	0.1057
(Intercept)	-1.85	1.20	-1.54	0.1242
Malaria prevalence	-0.18	0.13	-1.35	0.1780
Precipitation – second principal component	0.35	0.28	1.25	0.2116
Precipitation – first principal component	-0.44	0.38	-1.18	0.2410
Healthcare access and quality index (HAQ)	-0.03	0.04	-0.95	0.3441
Precipitation – third principal component	-0.59	0.92	-0.64	0.5198
Percent agricultural land	-0.03	0.05	-0.59	0.5573
Elevation	0.26	0.46	0.56	0.5773
Probability of LASV presence in <i>Mastomys</i> <i>spp</i>	-0.07	0.15	-0.43	0.6651

NDVI – second principal component	-0.10	0.25	-0.41	0.6852
Occurrence of bushmeat hunting	-0.02	0.06	-0.34	0.7368
Temperature – third principal component	-0.15	0.45	-0.33	0.7446
NDVI – first principal component	0.02	0.09	0.24	0.8125
<i>Interaction terms</i>				
NDVI PC1:NDVI PC2	-0.05	0.07	-0.76	0.4478
NDVI PC1:Precipitation PC1	0.06	0.09	0.60	0.5499
NDVI PC1:Precipitation PC2	0.01	0.06	0.24	0.8119
NDVI PC1:Precipitation PC3	0.31	0.26	1.18	0.2402
NDVI PC1:Temperature PC1	-0.11	0.09	-1.25	0.2117
NDVI PC1:Temperature PC2	-0.12	0.09	-1.33	0.1854
NDVI PC1:Temperature PC3	-0.12	0.22	-0.52	0.6034
NDVI PC1:Elevation	-0.28	0.18	-1.56	0.1202
NDVI PC1:Longitude	-0.30	0.15	-1.95	0.0518
NDVI PC1:Latitude	0.61	0.50	1.22	0.2243
NDVI PC1:Mastomys occurrence	-0.02	0.07	-0.35	0.7241
NDVI PC1:Mastomys infection	0.01	0.07	0.14	0.8875
NDVI PC1:Improved housing	0.00	0.04	-0.12	0.9043
NDVI PC1:Malaria prevalence	-0.20	0.08	-2.43	0.0159
NDVI PC2:Precipitation PC1	0.23	0.27	0.87	0.3847
NDVI PC2:Precipitation PC2	-0.07	0.17	-0.40	0.6913
NDVI PC2:Precipitation PC3	0.36	0.65	0.55	0.5825
NDVI PC2:Temperature PC1	-0.41	0.23	-1.79	0.0742

NDVI PC2:Temperature PC2	0.48	0.19	2.50	0.0130
NDVI PC2:Temperature PC3	-0.42	0.50	-0.84	0.4005
NDVI PC2:Elevation	0.18	0.55	0.32	0.7480
NDVI PC2:Longitude	0.51	0.39	1.30	0.1936
NDVI PC2:Latitude	2.44	1.16	2.10	0.0364
NDVI PC2:Mastomys occurrence	-0.27	0.19	-1.45	0.1470
NDVI PC2:Mastomys infection	-0.03	0.19	-0.13	0.8956
NDVI PC2:Improved housing	-0.08	0.11	-0.70	0.4837
NDVI PC2:Malaria prevalence	-0.42	0.18	-2.32	0.0209
Precipitation PC1:Precipitation PC2	-0.25	0.12	-2.07	0.0396
Precipitation PC1:Precipitation PC3	0.41	0.21	1.98	0.0494
Precipitation PC1:Temperature PC1	0.11	0.20	0.52	0.6063
Precipitation PC1:Temperature PC2	-0.03	0.20	-0.16	0.8705
Precipitation PC1:Temperature PC3	0.43	0.44	0.98	0.3292
Precipitation PC1:Elevation	0.08	0.37	0.21	0.8345
Precipitation PC1:Longitude	0.14	0.26	0.54	0.5897
Precipitation PC1:Latitude	0.06	0.56	0.11	0.9148
Precipitation PC1:Mastomys occurrence	-0.18	0.16	-1.14	0.2535
Precipitation PC1:Mastomys infection	0.00	0.14	-0.02	0.9870
Precipitation PC1:Improved housing	-0.06	0.11	-0.50	0.6195
Precipitation PC1:Malaria prevalence	0.16	0.15	1.10	0.2740
Precipitation PC2:Precipitation PC3	-0.11	0.21	-0.51	0.6074
Precipitation PC2:Temperature PC1	0.49	0.13	3.78	0.0002

Precipitation PC2:Temperature PC2	-0.45	0.14	-3.27	0.0012
Precipitation PC2:Temperature PC3	0.31	0.31	0.99	0.3212
Precipitation PC2:Elevation	0.18	0.25	0.72	0.4727
Precipitation PC2:Longitude	-0.60	0.25	-2.35	0.0197
Precipitation PC2:Latitude	-1.84	0.59	-3.10	0.0022
Precipitation PC2:Mastomys occurrence	0.06	0.12	0.54	0.5910
Precipitation PC2:Mastomys infection	0.08	0.10	0.75	0.4517
Precipitation PC2:Improved housing	0.02	0.07	0.26	0.7957
Precipitation PC2:Malaria prevalence	0.07	0.12	0.62	0.5341
Precipitation PC3:Temperature PC1	-0.36	0.47	-0.75	0.4512
Precipitation PC3:Temperature PC2	0.96	0.42	2.28	0.0236
Precipitation PC3:Temperature PC3	-1.21	1.25	-0.97	0.3325
Precipitation PC3:Elevation	1.70	0.98	1.73	0.0845
Precipitation PC3:Longitude	1.61	0.94	1.72	0.0865
Precipitation PC3:Latitude	3.31	2.13	1.55	0.1216
Precipitation PC3:Mastomys occurrence	0.48	0.40	1.18	0.2384
Precipitation PC3:Mastomys infection	0.43	0.31	1.37	0.1727
Precipitation PC3:Improved housing	0.28	0.25	1.14	0.2534
Precipitation PC3:Malaria prevalence	0.37	0.29	1.28	0.2015
Temperature PC1:Temperature PC2	0.14	0.07	1.84	0.0673
Temperature PC1:Temperature PC3	-0.12	0.35	-0.33	0.7454
Temperature PC1:Elevation	0.09	0.13	0.69	0.4906
Temperature PC1:Longitude	-0.37	0.24	-1.54	0.1253

Temperature PC1:Latitude	0.18	0.50	0.36	0.7155
Temperature PC1:Mastomys occurrence	-0.17	0.15	-1.14	0.2564
Temperature PC1:Mastomys infection	0.12	0.13	0.91	0.3636
Temperature PC1:Improved housing	0.11	0.10	1.06	0.2924
Temperature PC1:Malaria prevalence	-0.17	0.16	-1.06	0.2886
Temperature PC2:Temperature PC3	0.65	0.33	1.94	0.0533
Temperature PC2:Elevation	0.15	0.20	0.76	0.4468
Temperature PC2:Longitude	-0.20	0.26	-0.78	0.4350
Temperature PC2:Latitude	-0.38	0.56	-0.67	0.5026
Temperature PC2:Mastomys occurrence	-0.29	0.13	-2.26	0.0248
Temperature PC2:Mastomys infection	-0.12	0.11	-1.04	0.2974
Temperature PC2:Improved housing	-0.23	0.08	-2.98	0.0032
Temperature PC2:Malaria prevalence	-0.12	0.14	-0.86	0.3883
Temperature PC3:Elevation	0.26	0.92	0.29	0.7756
Temperature PC3:Longitude	0.95	0.72	1.31	0.1921
Temperature PC3:Latitude	1.03	2.03	0.51	0.6124
Temperature PC3:Mastomys occurrence	-0.39	0.39	-1.01	0.3153
Temperature PC3:Mastomys infection	0.47	0.37	1.27	0.2045
Temperature PC3:Improved housing	0.41	0.33	1.24	0.2179
Temperature PC3:Malaria prevalence	-0.11	0.32	-0.35	0.7273
Elevation:Longitude	-0.67	0.57	-1.17	0.2447
Elevation:Latitude	1.52	1.29	1.18	0.2400
Elevation:Mastomys occurrence	-0.81	0.28	-2.94	0.0036

Elevation:Mastomys infection	-0.14	0.23	-0.59	0.5548
Elevation:Improved housing	-0.23	0.21	-1.09	0.2765
Elevation:Malaria prevalence	-0.79	0.38	-2.07	0.0392
Longitude:Latitude	-0.07	0.75	-0.09	0.9253
Longitude:Mastomys occurrence	-0.29	0.25	-1.16	0.2490
Longitude:Mastomys infection	-0.28	0.21	-1.34	0.1817
Longitude:Improved housing	-0.06	0.22	-0.25	0.8045
Longitude:Malaria prevalence	0.15	0.31	0.48	0.6320
Latitude:Mastomys occurrence	0.31	0.82	0.38	0.7020
Latitude:Mastomys infection	-0.33	0.59	-0.56	0.5734
Latitude:Improved housing	-0.66	0.55	-1.20	0.2298
Latitude:Malaria prevalence	0.51	0.77	0.65	0.5133
Mastomys occurrence:Mastomys infection	0.10	0.12	0.81	0.4173
Mastomys occurrence:Improved housing	0.05	0.07	0.77	0.4450
Mastomys occurrence:Malaria prevalence	0.01	0.12	0.07	0.9457
Mastomys infection:Improved housing	0.12	0.07	1.64	0.1015
Mastomys infection:Malaria prevalence	0.22	0.12	1.83	0.0677
Improved housing:Malaria prevalence	-0.01	0.08	-0.08	0.9325

Table S7. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is 0%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Country	Admin1	Annual Lassa Fever incidence rate (per 1,000)					
		Seroreverted – No Immunity			Seroreverted – Partial Immunity		
		Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)	Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)
Nigeria	Ondo	3.9 (3.3 – 4.4)	5.0 (4.1 – 6.1)	5.6 (4.5 – 6.9)	3.9 (3.3 – 4.4)	5.0 (4.1 – 6.1)	5.6 (4.5 – 6.9)
Mali	Sikasso	3.1 (2.7 – 3.4)	3.6 (3.1 – 4.1)	3.9 (3.3 – 4.4)	3.1 (2.7 – 3.4)	3.6 (3.1 – 4.1)	3.9 (3.3 – 4.4)
Sierra Leone	Southern	2.7 (2.2 – 3.1)	3.2 (2.5 – 3.9)	3.4 (2.7 – 4.2)	2.7 (2.2 – 3.1)	3.2 (2.5 – 3.9)	3.4 (2.7 – 4.2)
Guinea	Faranah	2.3 (2.2 – 2.5)	2.7 (2.4 – 2.9)	2.8 (2.6 – 3.1)	2.3 (2.2 – 2.5)	2.7 (2.4 – 2.9)	2.8 (2.6 – 3.1)
Cote d'Ivoire	Lacs	2.2 (1.7 – 2.8)	2.5 (1.9 – 3.3)	2.6 (2.0 – 3.5)	2.2 (1.7 – 2.8)	2.5 (1.9 – 3.3)	2.6 (2.0 – 3.6)
Liberia	Grand Bassa	2.1 (0.4 – 6.5)	2.4 (0.4 – 49.7)	2.5 (0.4 – 70.8)	2.1 (0.4 – 6.5)	2.4 (0.4 – 49.7)	2.5 (0.4 – 70.8)
Guinea	Nzerekore	1.8 (1.7 – 1.8)	1.9 (1.8 – 2.0)	2.0 (1.9 – 2.1)	1.8 (1.7 – 1.8)	1.9 (1.8 – 2.0)	2.0 (1.9 – 2.1)

Liberia	Bong	1.7 (0.3 – 6.5)	1.9 (0.3 – 47.5)	2.0 (0.3 – 67.8)	1.7 (0.3 – 6.5)	1.9 (0.3 – 47.7)	2.0 (0.3 – 67.6)
Sierra Leone	Eastern	1.7 (1.6 – 1.7)	1.8 (1.7 – 1.9)	1.9 (1.8 – 2.0)	1.7 (1.6 – 1.8)	1.8 (1.7 – 1.9)	1.9 (1.8 – 2.0)
Nigeria	Ebonyi	1.2 (0.2 – 6.9)	1.3 (0.2 – 21.6)	1.3 (0.2 – 28.7)	1.2 (0.2 – 6.8)	1.3 (0.2 – 21.6)	1.3 (0.2 – 28.8)
Nigeria	Taraba	1.1 (0.1 – 7.0)	1.2 (0.1 – 24.8)	1.2 (0.1 – 33.5)	1.1 (0.1 – 7.0)	1.2 (0.1 – 24.8)	1.2 (0.1 – 33.5)
Nigeria	Edo	1.1 (0.9 – 1.3)	1.1 (1.0 – 1.3)	1.2 (1.0 – 1.4)	1.1 (0.9 – 1.3)	1.1 (1.0 – 1.3)	1.2 (1.0 – 1.4)
Benin	Borgou	1.1 (0.2 – 6.1)	1.1 (0.2 – 22.8)	1.1 (0.2 – 31.0)	1.1 (0.2 – 6.0)	1.1 (0.2 – 22.8)	1.1 (0.2 – 31.1)
Sierra Leone	Northern	1.0 (0.9 – 1.0)	1.0 (0.9 – 1.1)	1.0 (1.0 – 1.1)	1.0 (0.9 – 1.0)	1.0 (0.9 – 1.1)	1.0 (1.0 – 1.1)
Liberia	Nimba	1.0 (0.1 – 6.2)	1.0 (0.1 – 25.0)	1.0 (0.1 – 34.2)	1.0 (0.1 – 6.1)	1.0 (0.1 – 25.2)	1.0 (0.1 – 34.3)
Sierra Leone	Western	1.0 (0.6 – 1.5)	1.0 (0.6 – 1.6)	1.0 (0.6 – 1.6)	1.0 (0.6 – 1.5)	1.0 (0.6 – 1.6)	1.0 (0.6 – 1.6)
Guinea	Kankan	0.9 (0.7 – 1.2)	1.0 (0.7 – 1.3)	1.0 (0.8 – 1.3)	1.0 (0.7 – 1.2)	1.0 (0.7 – 1.3)	1.0 (0.8 – 1.3)
Guinea	Kindia	0.9 (0.8 – 1.1)	1.0 (0.9 – 1.1)	1.0 (0.9 – 1.2)	0.9 (0.8 – 1.1)	1.0 (0.9 – 1.1)	1.0 (0.9 – 1.2)
Ghana	Ashanti	0.9 (0.4 – 1.7)	1.0 (0.4 – 1.9)	1.0 (0.4 – 2.0)	0.9 (0.4 – 1.7)	1.0 (0.4 – 1.9)	1.0 (0.4 – 2.0)
Ghana	Eastern	0.8 (0.4 – 1.3)	0.9 (0.5 – 1.5)	0.9 (0.5 – 1.5)	0.8 (0.4 – 1.3)	0.9 (0.5 – 1.5)	0.9 (0.5 – 1.5)

Table S8. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is 0%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Country	Admin1	Admin2	Annual Lassa Fever incidence rate (per 1,000)					
			Seroreverted – No Immunity			Seroreverted – Partial Immunity		
			Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)	Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)
Sierra Leone	Southern	Moyamba	4.7 (4.0 – 5.2)	7.5 (5.6 – 9.7)	8.8 (6.3 – 11.8)	4.7 (4.1 – 5.2)	7.5 (5.6 – 9.6)	8.8 (6.3 – 11.9)
Nigeria	Ondo	Ose	4.6 (3.9 – 5.2)	6.6 (5.1 – 8.3)	7.6 (5.6 – 9.7)	4.6 (3.9 – 5.1)	6.6 (5.1 – 8.2)	7.6 (5.7 – 9.8)
Sierra Leone	Northern	Bombali	3.7 (2.5 – 4.8)	4.9 (2.9 – 7.6)	5.5 (3.0 – 9.1)	3.7 (2.5 – 4.8)	4.9 (2.9 – 7.6)	5.5 (3.1 – 9.0)
Sierra Leone	Eastern	Kono	3.4 (0.2 – 5.7)	4.3 (0.2 – 13.4)	4.7 (0.2 – 17.1)	3.4 (0.2 – 5.7)	4.3 (0.2 – 13.3)	4.7 (0.2 – 17.1)
Sierra Leone	Northern	Koinadugu	3.4 (1.4 – 4.9)	4.3 (1.5 – 8.2)	4.7 (1.5 – 9.7)	3.4 (1.4 – 4.9)	4.2 (1.5 – 8.1)	4.6 (1.5 – 9.7)

Nigeria	Edo	Esan West	3.3 (2.8 – 3.7)	4.1 (3.3 – 4.8)	4.4 (3.6 – 5.3)	3.3 (2.8 – 3.8)	4.0 (3.3 – 4.8)	4.4 (3.6 – 5.3)
Liberia	Bong	Suakoko	3.3 (0.9 – 6.5)	4.1 (0.9 – 49.8)	4.6 (1.0 – 70.9)	3.3 (0.9 – 6.5)	4.2 (1.0 – 49.8)	4.6 (1.0 – 70.9)
Guinea	Nzerekore	Macenta	3.2 (3.0 – 3.5)	4.0 (3.6 – 4.4)	4.4 (3.9 – 4.9)	3.2 (3.0 – 3.5)	4.0 (3.6 – 4.4)	4.4 (3.9 – 4.9)
Sierra Leone	Southern	Pujehun	3.1 (1.1 – 4.9)	3.8 (1.2 – 8.1)	4.2 (1.2 – 9.7)	3.2 (1.1 – 4.9)	3.8 (1.2 – 8.1)	4.2 (1.2 – 9.7)
Mali	Sikasso	Bougouni	3.1 (2.7 – 3.4)	3.6 (3.1 – 4.1)	3.8 (3.3 – 4.4)	3.1 (2.7 – 3.4)	3.6 (3.1 – 4.1)	3.8 (3.3 – 4.4)
Sierra Leone	Western	Western Rural	2.4 (0.1 – 5.2)	2.8 (0.1 – 9.5)	2.9 (0.1 – 11.6)	2.4 (0.1 – 5.2)	2.8 (0.1 – 9.5)	2.9 (0.1 – 11.6)
Liberia	Grand Bassa	District #3	2.4 (0.5 – 6.4)	2.7 (0.6 – 44.6)	2.9 (0.6 – 63.0)	2.4 (0.5 – 6.4)	2.7 (0.6 – 44.6)	2.9 (0.6 – 62.8)
Guinea	Faranah	Faranah	2.4 (2.2 – 2.5)	2.7 (2.4 – 2.9)	2.8 (2.6 – 3.1)	2.4 (2.1 – 2.5)	2.7 (2.4 – 2.9)	2.8 (2.6 – 3.1)
Cote d'Ivoire	Montagnes	Cavally	2.3 (1.7 – 2.9)	2.7 (1.9 – 3.5)	2.8 (2.0 – 3.8)	2.3 (1.7 – 2.9)	2.7 (1.9 – 3.5)	2.8 (2.0 – 3.8)
Nigeria	Ondo	Owo	2.3 (1.4 – 3.2)	2.6 (1.5 – 3.9)	2.7 (1.5 – 4.2)	2.3 (1.4 – 3.2)	2.6 (1.5 – 3.9)	2.7 (1.5 – 4.2)
Sierra Leone	Eastern	Kailahun	2.3 (1.5 – 3.1)	2.6 (1.6 – 3.7)	2.7 (1.6 – 4.0)	2.3 (1.5 – 3.1)	2.5 (1.6 – 3.7)	2.7 (1.6 – 4.0)
Guinea	Kindia	Kindia	2.1 (1.7 – 2.6)	2.4 (1.9 – 2.9)	2.5 (2.0 – 3.2)	2.1 (1.7 – 2.5)	2.4 (1.9 – 2.9)	2.5 (2.0 – 3.1)

Guinea	Nzerekore	Gueckedou	1.9 (1.8 – 2.1)	2.1 (2.0 – 2.3)	2.2 (2.0 – 2.4)	1.9 (1.8 – 2.1)	2.1 (2.0 – 2.3)	2.2 (2.0 – 2.4)
Guinea	Nzerekore	Lola	1.9 (1.7 – 2.2)	2.1 (1.8 – 2.5)	2.2 (1.9 – 2.6)	1.9 (1.6 – 2.2)	2.1 (1.8 – 2.4)	2.2 (1.9 – 2.6)
Cote d'Ivoire	Montagnes	Guemon	1.9 (0.9 – 3.0)	2.1 (0.9 – 3.7)	2.2 (1.0 – 3.9)	1.9 (0.9 – 3.0)	2.1 (0.9 – 3.6)	2.2 (1.0 – 3.9)

Table S9. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is 3%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Country	Admin1	Annual Lassa Fever incidence rate (per 1,000)					
		Seroreverted – No Immunity			Seroreverted – Partial Immunity		
		Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)	Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)
Nigeria	Ondo	6.7 (5.6 – 7.5)	8.8 (7.0 – 10.8)	9.9 (7.6 – 12.3)	5.9 (5.1 – 6.6)	8.0 (6.4 – 9.8)	9.1 (7.1 – 11.3)
Mali	Sikasso	5.0 (4.5 – 5.6)	5.9 (5.1 – 6.8)	6.4 (5.5 – 7.4)	4.6 (4.2 – 5.1)	5.5 (4.8 – 6.3)	6.0 (5.2 – 6.9)
Sierra Leone	Southern	4.3 (3.6 – 5.1)	5.0 (4.0 – 6.2)	5.3 (4.2 – 6.8)	3.9 (3.3 – 4.6)	4.6 (3.8 – 5.7)	5.0 (4.0 – 6.2)
Guinea	Faranah	4.3 (4.0 – 4.6)	5.0 (4.5 – 5.4)	5.3 (4.8 – 5.8)	3.9 (3.7 – 4.2)	4.6 (4.2 – 5.0)	4.9 (4.5 – 5.4)
Cote d'Ivoire	Lacs	3.6 (2.8 – 4.5)	4.1 (3.0 – 5.2)	4.3 (3.1 – 5.6)	3.3 (2.6 – 4.1)	3.8 (2.9 – 4.9)	4.0 (3.0 – 5.3)
Guinea	Nzerekore	3.0 (2.9 – 3.1)	3.3 (3.1 – 3.5)	3.4 (3.3 – 3.6)	2.8 (2.7 – 2.9)	3.1 (3.0 – 3.3)	3.3 (3.1 – 3.4)

Sierra Leone	Eastern	2.8 (2.6 – 2.9)	3.0 (2.8 – 3.2)	3.1 (2.9 – 3.3)	2.6 (2.5 – 2.7)	2.9 (2.7 – 3.0)	3.0 (2.8 – 3.1)
Liberia	Grand Bassa	2.4 (0.3 – 6.9)	2.6 (0.3 – 9.6)	2.7 (0.3 – 11.0)	2.3 (0.4 – 6.0)	2.5 (0.4 – 8.7)	2.6 (0.3 – 10.0)
Liberia	Bong	1.9 (0.3 – 6.8)	2.0 (0.3 – 9.6)	2.0 (0.3 – 10.9)	1.8 (0.3 – 6.0)	1.9 (0.3 – 8.7)	2.0 (0.3 – 10.0)
Nigeria	Edo	1.8 (1.6 – 2.1)	1.9 (1.6 – 2.2)	2.0 (1.7 – 2.3)	1.8 (1.5 – 2.0)	1.9 (1.6 – 2.2)	1.9 (1.6 – 2.2)
Ghana	Ashanti	1.7 (0.7 – 3.1)	1.8 (0.7 – 3.4)	1.8 (0.7 – 3.6)	1.6 (0.7 – 2.9)	1.7 (0.7 – 3.2)	1.8 (0.7 – 3.4)
Sierra Leone	Western	1.6 (1.0 – 2.5)	1.7 (1.0 – 2.7)	1.7 (1.0 – 2.8)	1.6 (0.9 – 2.4)	1.6 (1.0 – 2.6)	1.7 (1.0 – 2.7)
Guinea	Kindia	1.6 (1.4 – 1.8)	1.7 (1.5 – 1.9)	1.7 (1.5 – 1.9)	1.5 (1.4 – 1.8)	1.6 (1.4 – 1.8)	1.7 (1.4 – 1.9)
Sierra Leone	Northern	1.6 (1.5 – 1.7)	1.6 (1.5 – 1.8)	1.7 (1.6 – 1.8)	1.5 (1.4 – 1.6)	1.6 (1.5 – 1.7)	1.6 (1.5 – 1.8)
Guinea	Kankan	1.5 (1.2 – 2.0)	1.6 (1.2 – 2.1)	1.6 (1.2 – 2.1)	1.5 (1.2 – 1.9)	1.6 (1.2 – 2.0)	1.6 (1.2 – 2.0)
Ghana	Eastern	1.5 (0.7 – 2.4)	1.6 (0.7 – 2.6)	1.6 (0.7 – 2.7)	1.5 (0.7 – 2.3)	1.5 (0.7 – 2.5)	1.6 (0.7 – 2.6)
Nigeria	Ebonyi	1.4 (0.2 – 7.4)	1.4 (0.2 – 10.3)	1.5 (0.2 – 11.8)	1.4 (0.2 – 6.4)	1.4 (0.2 – 9.4)	1.4 (0.2 – 10.8)
Liberia	Nimba	1.2 (0.1 – 6.4)	1.2 (0.1 – 8.6)	1.3 (0.1 – 9.7)	1.2 (0.1 – 5.6)	1.2 (0.1 – 7.8)	1.2 (0.1 – 8.8)
Nigeria	Borno	1.1 (0.7 – 1.6)	1.1 (0.7 – 1.7)	1.2 (0.7 – 1.7)	1.1 (0.7 – 1.6)	1.1 (0.7 – 1.6)	1.1 (0.7 – 1.7)
Benin	Borgou	1.1 (0.2 – 6.3)	1.1 (0.2 – 8.4)	1.2 (0.2 – 9.5)	1.1 (0.2 – 5.5)	1.1 (0.2 – 7.7)	1.1 (0.2 – 8.7)

Table S10. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is 3%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Country	Admin1	Admin2	Annual Lassa Fever incidence rate (per 1,000)					
			Seroreverted – No Immunity			Seroreverted – Partial Immunity		
			Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)	Seropos. – Full Immunity	Seropos. – Part. Immunity (Hi)	Seropos. – Part. Immunity (Lo)
Nigeria	Ondo	Ose	8.3 (6.8 – 9.5)	12.9 (9.2 – 17.1)	15.0 (10.2 – 20.8)	7.2 (6.1 – 8.0)	11.7 (8.4 – 15.7)	13.9 (9.5 – 19.5)
Sierra Leone	Southern	Moyamba	7.9 (6.7 – 8.9)	12.4 (9.2 – 16.4)	14.6 (10.4 – 19.9)	6.8 (5.9 – 7.4)	11.3 (8.3 – 14.8)	13.4 (9.6 – 18.4)
Nigeria	Edo	Esan West	6.4 (5.4 – 7.4)	8.4 (6.6 – 10.3)	9.3 (7.2 – 11.8)	5.7 (4.9 – 6.4)	7.6 (6.1 – 9.4)	8.6 (6.7 – 10.9)
Sierra Leone	Northern	Bombali	6.4 (4.0 – 8.3)	8.6 (4.6 – 13.7)	9.6 (4.8 – 16.3)	5.6 (3.7 – 7.0)	7.8 (4.3 – 12.5)	8.9 (4.5 – 15.0)
Sierra Leone	Northern	Koinadugu	6.0 (2.1 – 8.8)	7.6 (2.2 – 15.8)	8.5 (2.3 – 19.2)	5.3 (2.0 – 7.4)	7.0 (2.2 – 14.4)	7.9 (2.2 – 17.9)
Guinea	Nzerekore	Macenta	5.9 (5.4 – 6.4)	7.6 (6.7 – 8.4)	8.4 (7.3 – 9.5)	5.2 (4.8 – 5.6)	6.9 (6.2 – 7.7)	7.7 (6.8 – 8.7)

Mali	Sikasso	Bougouni	5.0 (4.5 – 5.6)	6.0 (5.2 – 6.8)	6.4 (5.5 – 7.4)	4.7 (4.2 – 5.1)	5.6 (4.9 – 6.3)	6.0 (5.2 – 6.9)
Sierra Leone	Southern	Pujehun	4.7 (1.6 – 7.7)	5.6 (1.6 – 11.9)	6.0 (1.7 – 13.8)	4.3 (1.5 – 6.6)	5.1 (1.6 – 10.8)	5.6 (1.7 – 12.8)
Guinea	Faranah	Faranah	4.3 (3.9 – 4.6)	5.0 (4.5 – 5.4)	5.3 (4.8 – 5.8)	3.9 (3.6 – 4.2)	4.6 (4.2 – 5.0)	5.0 (4.5 – 5.4)
Sierra Leone	Eastern	Kono	4.2 (0.2 – 9.2)	4.9 (0.2 – 18.2)	5.2 (0.2 – 22.5)	3.9 (0.2 – 7.7)	4.6 (0.2 – 16.7)	4.9 (0.2 – 21.0)
Nigeria	Ondo	Owo	3.9 (2.4 – 5.4)	4.4 (2.6 – 6.6)	4.7 (2.6 – 7.2)	3.6 (2.3 – 4.9)	4.1 (2.5 – 6.2)	4.4 (2.6 – 6.7)
Sierra Leone	Eastern	Kailahun	3.8 (2.4 – 5.2)	4.4 (2.6 – 6.4)	4.6 (2.7 – 7.0)	3.5 (2.3 – 4.7)	4.1 (2.5 – 5.9)	4.3 (2.5 – 6.5)
Cote d'Ivoire	Montagnes	Cavally	3.8 (2.8 – 4.9)	4.3 (3.0 – 5.8)	4.5 (3.1 – 6.3)	3.5 (2.6 – 4.4)	4.0 (2.9 – 5.4)	4.3 (3.0 – 5.8)
Guinea	Kindia	Kindia	3.5 (2.9 – 4.2)	3.9 (3.1 – 4.8)	4.1 (3.3 – 5.1)	3.2 (2.7 – 3.8)	3.7 (3.0 – 4.5)	3.9 (3.1 – 4.8)
Sierra Leone	Western	Rural	3.5 (0.1 – 8.5)	3.9 (0.1 – 14.7)	4.1 (0.1 – 17.6)	3.2 (0.1 – 7.2)	3.6 (0.1 – 13.3)	3.9 (0.1 – 16.3)
Liberia	Bong	Suakoko	3.4 (0.9 – 7.2)	3.8 (0.9 – 10.4)	4.0 (0.9 – 12.0)	3.2 (0.9 – 6.2)	3.6 (0.9 – 9.5)	3.8 (0.9 – 11.0)
Guinea	Nzerekore	Gueckedou	3.2 (3.0 – 3.5)	3.6 (3.3 – 3.9)	3.8 (3.4 – 4.1)	3.0 (2.8 – 3.3)	3.4 (3.1 – 3.7)	3.6 (3.3 – 3.9)
Guinea	Nzerekore	Lola	3.1 (2.7 – 3.5)	3.5 (2.9 – 4.0)	3.6 (3.0 – 4.2)	2.9 (2.5 – 3.3)	3.3 (2.8 – 3.8)	3.4 (2.9 – 4.0)

Cote d'Ivoire	Montagnes	Guemon	3.1 (1.5–4.9)	3.4 (1.5–5.9)	3.5 (1.6–6.3)	2.9 (1.4–4.4)	3.2 (1.5–5.4)	3.4 (1.5–5.9)
Guinea	Nzerekore	Yamou	2.9 (2.6–3.2)	3.2 (2.8–3.6)	3.3 (2.9–3.7)	2.7 (2.4–3.0)	3.0 (2.6–3.4)	3.1 (2.8–3.5)




Figure S1. Maps of FOI projections from LF case/death data and reporting probabilities at the (A) 1st and (B) 2nd administrative levels with seroreversion = 0%.




Figure S2. Maps of FOI projections from LF case/death data and reporting probabilities at the (A) 1st and (B) 2nd administrative levels with seroreversion = 3%.




Figure S3. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities for each of the eight statistical models (plus a null intercept-only model) included in our analysis. Plots are restricted to FOI estimates that were used in model fitting and do not include data held out for model validation. Results are for the 2nd administrative level and a 6% seroreversion rate.




Figure S4. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities for each of the eight statistical models (plus a null intercept-only model) included in our analysis. Plots are restricted to FOI estimates that were used in model fitting and do not include data held out for model validation. Results are for the 2nd administrative level and a 6% seroreversion rate.




Figure S5. Scatterplots showing the cross-validation performance of each statistical regression model.

Regression predictions of FOI for withheld data are on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities on the y-axis. Results are for the 1st administrative level and a 6% seroreversion rate.




Figure S6. Scatterplots showing the cross-validation performance of each statistical regression model.

Regression predictions of FOI for withheld data are on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities on the y-axis. Results are for the 2nd administrative level and a 6% seroreversion rate.




Figure S7. Map of ensemble model-based FOI estimates at the (A) 1st and (B) 2nd administrative levels with seroreversion = 0%.




Figure S8. Map of ensemble model-based FOI estimates at the (A) 1st and (B) 2nd administrative levels with seroreversion = 3%.




Figure S9. Map of ensemble model-based FOI estimates at the (A) 1st and (B) 2nd administrative levels with seroreversion = 6%.

References

1. Garry RF. Lassa fever — the road ahead. *Nat Rev Microbiol*. 2023;21(2):87-96. doi:10.1038/s41579-022-00789-8
2. WHO. Lassa fever. Accessed January 30, 2024. <https://www.who.int/health-topics/lassa-fever>
3. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A Prospective Study of the Epidemiology and Ecology of Lassa Fever. *The Journal of Infectious Diseases*. 1987;155(3):437-444. doi:10.1093/infdis/155.3.437
4. US CDC. Lassa Fever | CDC. April 26, 2022. Accessed January 30, 2024. <https://www.cdc.gov/vhf/lassa/index.html>
5. Redding DW, Gibb R, Dan-Nwafor CC, et al. Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria. *Nat Commun*. 2021;12(1):5759. doi:10.1038/s41467-021-25910-y
6. LaVergne SM, Sakabe S, Momoh M, et al. Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors. *PLOS Neglected Tropical Diseases*. 2022;16(11):e0010882. doi:10.1371/journal.pntd.0010882
7. Safronetz D, Sogoba N, Diawara SI, et al. Annual Incidence of Lassa Virus Infection in Southern Mali. *Am J Trop Med Hyg*. 2017;96(4):944-946. doi:10.4269/ajtmh.16-0821
8. Shaffer JG, Schieffelin JS, Momoh M, et al. Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019. *Microorganisms*. 2021;9(3):586. doi:10.3390/microorganisms9030586
9. Shaffer JG, Schieffelin JS, Gbakie M, et al. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. *PLOS ONE*. 2019;14(3):e0214284. doi:10.1371/journal.pone.0214284

10. Sigfrid L, Moore C, Salam AP, et al. A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks—results from the Lassa fever pilot. *BMC Medicine*. 2019;17(1):107. doi:10.1186/s12916-019-1338-1
11. Siddle KJ, Eromon P, Barnes KG, et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. *New England Journal of Medicine*. 2018;379(18):1745-1753. doi:10.1056/NEJMoa1804498
12. Dalhat MM, Olayinka A, Meremikwu MM, et al. Epidemiological trends of Lassa fever in Nigeria, 2018–2021. *PLOS ONE*. 2022;17(12):e0279467. doi:10.1371/journal.pone.0279467
13. Koch MR, Kanneh L, Wise PH, et al. Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. *PLOS Neglected Tropical Diseases*. 2021;15(7):e0009576. doi:10.1371/journal.pntd.0009576
14. Penfold S, Adegnika AA, Asogun D, et al. A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)—Study protocol. *PLoS One*. 2023;18(3):e0283643. doi:10.1371/journal.pone.0283643
15. Goios A, Varma A, Kagia C, Otiende M, Suykerbuyk P. Enable Lassa Research Programme Mid-term Workshop. Published online 2022. Accessed August 12, 2024. https://media.tghn.org/medialibrary/2023/03/CEPI_Enable_2022_Abuja_Report_Final.pdf
16. Lecompte E, Fichet-Calvet E, Daffis S, et al. *Mastomys natalensis* and Lassa Fever, West Africa. *Emerging Infectious Diseases*. 2006;12(12):1971-1974. doi:10.3201/eid1212.060812

17. Fichet-Calvet E, Lecompte E, Koivogui L, et al. Fluctuation of abundance and Lassa virus prevalence in *Mastomys natalensis* in Guinea, West Africa. *Vector-Borne and Zoonotic Diseases*. 2007;7(2):119-128.
18. Fichet-Calvet E, Becker-Ziaja B, Koivogui L, Günther S. Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. *Vector Borne Zoonotic Dis*. 2014;14(9):665-674.
doi:10.1089/vbz.2013.1484
19. Clark J, Yakob L, Douno M, et al. Domestic risk factors for increased rodent abundance in a Lassa fever endemic region of rural Upper Guinea. *Sci Rep*. 2021;11(1):20698. doi:10.1038/s41598-021-00113-z
20. Safronetz D, Sogoba N, Lopez JE, et al. Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. *PLOS Neglected Tropical Diseases*. 2013;7(12):e2582.
doi:10.1371/journal.pntd.0002582
21. Mariën J, Lo Iacono G, Rieger T, Magassouba N, Günther S, Fichet-Calvet E. Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea. *Emerg Microbes Infect*. 2020;9(1):1055-1064. doi:10.1080/22221751.2020.1766381
22. Happi AN, Olumade TJ, Ogunsanya OA, et al. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. *Microbiology Spectrum*. 2022;10(4):e00366-22. doi:10.1128/spectrum.00366-22
23. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A Prospective Study of the Epidemiology and Ecology of Lassa Fever. *The Journal of Infectious Diseases*. 1987;155(3):437-444.
doi:10.1093/infdis/155.3.437

24. Safronetz D, Sogoba N, Diawara SI, et al. Annual Incidence of Lassa Virus Infection in Southern Mali. *Am J Trop Med Hyg.* 2017;96(4):944-946. doi:10.4269/ajtmh.16-0821
25. Basinski AJ, Fichet-Calvet E, Sjodin AR, et al. Bridging the gap: Using reservoir ecology and human serosurveys to estimate Lassa virus spillover in West Africa. *PLOS Computational Biology.* 2021;17(3):e1008811. doi:10.1371/journal.pcbi.1008811
26. Peterson AT, Moses LM, Bausch DG. Mapping Transmission Risk of Lassa Fever in West Africa: The Importance of Quality Control, Sampling Bias, and Error Weighting. *PLOS ONE.* 2014;9(8):e100711. doi:10.1371/journal.pone.0100711
27. Fichet-Calvet. Risk Maps of Lassa Fever in West Africa. *PLOS Neglected Tropical Diseases.* 2009;3(3):e388. doi:10.1371/journal.pntd.0000388
28. Redding DW, Moses LM, Cunningham AA, Wood J, Jones KE. Environmental-mechanistic modelling of the impact of global change on human zoonotic disease emergence: a case study of Lassa fever. *Methods in Ecology and Evolution.* 2016;7(6):646-655. doi:10.1111/2041-210X.12549
29. Safronetz D, Sogoba N, Lopez JE, et al. Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. *PLOS Neglected Tropical Diseases.* 2013;7(12):e2582. doi:10.1371/journal.pntd.0002582
30. Lassa fever. WHO. Accessed April 27, 2023. <https://www.who.int/health-topics/lassa-fever>
31. Akhmetzhanov AR, Asai Y, Nishiura H. Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria. *Philos Trans R Soc Lond B Biol Sci.* 2019;374(1775):20180268. doi:10.1098/rstb.2018.0268
32. Lassa Fever | CDC. April 26, 2022. Accessed May 4, 2023. <https://www.cdc.gov/vhf/lassa/index.html>

33. Priority diseases. CEPI. Accessed May 4, 2023. https://cepi.net/research_dev/priority-diseases/
34. Hallam HJ, Hallam S, Rodriguez SE, et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. *npj Vaccines*. 2018;3(1):1-12. doi:10.1038/s41541-018-0049-5
35. Ramanathan R, Stibitz S, Pratt D, Roberts J. Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations. *Vaccine*. 2019;37(31):4256-4261. doi:10.1016/j.vaccine.2019.06.009
36. Disease outbreak - Lassa fever - Nigeria - 1 March 2018. WHO | Regional Office for Africa. March 24, 2023. Accessed March 27, 2023. <https://www.afro.who.int/health-topics/lassa-fever/outbreak/1-march-2018-nigeria>
37. Saleh F, Popoola BO, Arinze C, et al. Adapting public health response through lessons learnt: Nigeria's experience from Lassa fever and COVID-19. *BMJ Global Health*. 2022;7(Suppl 7):e007993. doi:10.1136/bmjgh-2021-007993
38. Garry RF. Lassa fever — the road ahead. *Nat Rev Microbiol*. 2023;21(2):87-96. doi:10.1038/s41579-022-00789-8
39. Siddle KJ, Eromon P, Barnes KG, et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. *N Engl J Med*. 2018;379(18):1745-1753. doi:10.1056/NEJMoa1804498
40. Kernéis S, Koivogui L, Magassouba N, et al. Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study. *PLOS Neglected Tropical Diseases*. 2009;3(11):e548. doi:10.1371/journal.pntd.0000548

41. Klempa B, Koulemou K, Auste B, et al. Seroepidemiological study reveals regional co-occurrence of Lassa- and Hantavirus antibodies in Upper Guinea, West Africa. *Tropical Medicine & International Health*. 2013;18(3):366-371. doi:10.1111/tmi.12045
42. Longet S, Leggio C, Bore JA, et al. Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea. *Emerg Infect Dis*. 2023;29(2):304-313. doi:10.3201/eid2902.212525
43. Lukashevich IS, Clegg JC, Sidibe K. Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. *J Med Virol*. 1993;40(3):210-217. doi:10.1002/jmv.1890400308
44. Fraser DW, Campbell CC, Monath TP, Goff PA, Gregg MB. Lassa Fever in the Eastern Province of Sierra Leone, 1970–1972: I. Epidemiologic Studies. *The American Journal of Tropical Medicine and Hygiene*. 1974;23(6):1131-1139. doi:10.4269/ajtmh.1974.23.1131
45. O’Hearn AE, Voorhees MA, Fetterer DP, et al. Serosurveillance of viral pathogens circulating in West Africa. *Virology*. 2016;13:163. doi:10.1186/s12985-016-0621-4
46. Grant DS, Engel EJ, Yerkes NR, et al. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study. *PLOS Neglected Tropical Diseases*. 2023;17(2):e0010938. doi:10.1371/journal.pntd.0010938
47. Sogoba N, Rosenke K, Adjemian J, et al. Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. *Emerg Infect Dis*. 2016;22(4):657-663. doi:10.3201/eid2204.151814
48. Tobin. Lassa fever in Nigeria: Insights into seroprevalence and risk factors in rural Edo State: A pilot study. Accessed January 31, 2023. <https://jmedtropics.org/article.asp?issn=2276-7096;year=2015;volume=17;issue=2;spage=51;epage=55;aulast=Tobin>

49. Merson L, Bourner J, Jalloh S, et al. Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design. *PLOS Neglected Tropical Diseases*. 2021;15(9):e0009788. doi:10.1371/journal.pntd.0009788
50. Nimo-Paintsil SC, Fichet-Calvet E, Borremans B, et al. Rodent-borne infections in rural Ghanaian farming communities. *PLOS ONE*. 2019;14(4):e0215224. doi:10.1371/journal.pone.0215224
51. Fichet-Calvet E, Rogers DJ. Risk Maps of Lassa Fever in West Africa. *PLoS Negl Trop Dis*. 2009;3(3):e388. doi:10.1371/journal.pntd.0000388
52. Mylne AQN, Pigott DM, Longbottom J, et al. Mapping the zoonotic niche of Lassa fever in Africa. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 2015;109(8):483-492. doi:10.1093/trstmh/trv047
53. Bangura U. *Molecular Epidemiology of Lassa Virus in the Mano River Union Area, West Africa*. doctoralThesis. Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky; 2022. Accessed January 22, 2023. <https://ediss.sub.uni-hamburg.de/handle/ediss/9660>
54. Demby AH, Inapogui A, Kargbo K, et al. Lassa Fever in Guinea: II. Distribution and Prevalence of Lassa Virus Infection in Small Mammals. *Vector-Borne and Zoonotic Diseases*. 2001;1(4):283-297. doi:10.1089/15303660160025912
55. Fichet-Calvet E, Becker-Ziaja B, Koivogui L, Günther S. Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. *Vector-Borne and Zoonotic Diseases*. 2014;14(9):665-674. doi:10.1089/vbz.2013.1484
56. Olayemi A, Oyeyiola A, Obadare A, et al. Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria. *Parasit Vectors*. 2018;11:416. doi:10.1186/s13071-018-2991-5

57. Mariën J, Lo Iacono G, Rieger T, Magassouba N, Günther S, Fichet-Calvet E. Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea. *Emerg Microbes Infect.* 2020;9(1):1055-1064. doi:10.1080/22221751.2020.1766381
58. Bangura U, Buanie J, Lamin J, et al. Lassa Virus Circulation in Small Mammal Populations in Bo District, Sierra Leone. *Biology (Basel)*. 2021;10(1):28. doi:10.3390/biology10010028
59. Agbonlahor DE, Erah A, Agba IM, et al. Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria. *J Vector Borne Dis.* 2017;54(2):146-150.
60. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study | PLOS Neglected Tropical Diseases. Accessed February 21, 2023. <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010938#pntd.0010938.s001>
61. Lerch A, ten Bosch QA, L'Azou Jackson M, et al. Projecting vaccine demand and impact for emerging zoonotic pathogens. *BMC Med.* 2022;20:202. doi:10.1186/s12916-022-02405-1
62. Shaffer JG, Schieffelin JS, Gbakie M, et al. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. *PLOS ONE*. 2019;14(3):e0214284. doi:10.1371/journal.pone.0214284
63. Worldpop - A Census Database. Accessed August 27, 2014. <http://www.worldpop.org.uk/data/methods/>
64. Redding DW, Gibb R, Dan-Nwafor CC, et al. Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria. *Nat Commun.* 2021;12:5759. doi:10.1038/s41467-021-25910-y

65. Fichet-Calvet E, Lecompte E, Koivogui L, et al. Fluctuation of Abundance and Lassa Virus Prevalence in *Mastomys natalensis* in Guinea, West Africa. *Vector-Borne and Zoonotic Diseases*. 2007;7(2):119-128. doi:10.1089/vbz.2006.0520
66. Weiss DJ, Nelson A, Gibson HS, et al. A global map of travel time to cities to assess inequalities in accessibility in 2015. *Nature*. 2018;553(7688):333-336. doi:10.1038/nature25181
67. Barber RM, Fullman N, Sorensen RJD, et al. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. *The Lancet*. 2017;390(10091):231-266. doi:10.1016/S0140-6736(17)30818-8
68. Olson DM, Dinerstein E, Wikramanayake ED, et al. Terrestrial Ecoregions of the World: A New Map of Life on Earth: A new global map of terrestrial ecoregions provides an innovative tool for conserving biodiversity. *BioScience*. 2001;51(11):933-938. doi:10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2
69. ESA. Land Cover CCI Product User Guide Version 2. Published online 2017. Accessed June 26, 2023. http://maps.elie.ucl.ac.be/CCI/viewer/download/ESACCI-LC-Ph2-PUGv2_2.0.pdf
70. Hansen MC, Potapov PV, Moore R, et al. High-resolution global maps of 21st-century forest cover change. *Science*. 2013;342(6160):850-853. doi:10.1126/science.1244693
71. Tusting LS, Bisanzio D, Alabaster G, et al. Mapping changes in housing in sub-Saharan Africa from 2000 to 2015. *Nature*. 2019;568(7752):391-394. doi:10.1038/s41586-019-1050-5
72. Smits J, Steendijk R. The International Wealth Index (IWI). *Soc Indic Res*. 2015;122(1):65-85. doi:10.1007/s11205-014-0683-x

73. Jagadesh S, Zhao C, Mulchandani R, Van Boeckel TP. Mapping Global Bushmeat Activities to Improve Zoonotic Spillover Surveillance by Using Geospatial Modeling. *Emerg Infect Dis.* 2023;29(4):742-750. doi:10.3201/eid2904.221022
74. Perkins TA, Huber JH, Tran QM, et al. Burden is in the eye of the beholder: Sensitivity of yellow fever disease burden estimates to modeling assumptions. *Sci Adv.* 2021;7(42):eabg5033. doi:10.1126/sciadv.abg5033
75. Ehichioya DU, Asogun DA, Ehimuan J, et al. Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005–2008. *Tropical Medicine & International Health.* 2012;17(8):1001-1004. doi:10.1111/j.1365-3156.2012.03010.x
76. Ugwu C, Olumade T, Nwakpakpa E, et al. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria. *Sci Rep.* 2022;12(1):22330. doi:10.1038/s41598-022-26045-w
77. Monath TP, Mertens PE, Patton R, et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. *The American Journal of Tropical Medicine and Hygiene.* 1973;22(6):773-779. doi:10.4269/ajtmh.1973.22.773
78. Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. *BMJ.* 1995;311(7009):857-859. doi:10.1136/bmj.311.7009.857
79. Dan-Nwafor CC, Ipadeola O, Smout E, et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: description and lessons learned, 2018. *International Journal of Infectious Diseases.* Published online March 28, 2019. doi:10.1016/j.ijid.2019.03.030

80. Sogoba N, Feldmann H, Safronetz D. Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity. *Zoonoses and Public Health*. 2012;59(s2):43-47. doi:10.1111/j.1863-2378.2012.01469.x
81. Sogoba N, Rosenke K, Adjemian J, et al. Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. *Emerg Infect Dis*. 2016;22(4):657-663. doi:10.3201/eid2204.151814
82. Lindgren F, Rue H, Lindström J. An explicit link between Gaussian fields and Gaussian Markov random fields: the stochastic partial differential equation approach. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*. 2011;73(4):423-498. doi:10.1111/j.1467-9868.2011.00777.x
83. Bhatt S, Cameron E, Flaxman SR, Weiss DJ, Smith DL, Gething PW. Improved prediction accuracy for disease risk mapping using Gaussian process stacked generalization. *Journal of The Royal Society Interface*. 2017;14(134):20170520. doi:10.1098/rsif.2017.0520
84. Barua S, Dénes A, Ibrahim MA. A seasonal model to assess intervention strategies for preventing periodic recurrence of Lassa fever. *Heliyon*. 2021;7(8):e07760. doi:10.1016/j.heliyon.2021.e07760
85. Leski TA, Stockelman MG, Moses LM, et al. Sequence Variability and Geographic Distribution of Lassa Virus, Sierra Leone. *Emerg Infect Dis*. 2015;21(4):609-618. doi:10.3201/eid2104.141469
86. Happi AN, Olumade TJ, Ogunsanya OA, et al. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. Anderson MZ, ed. *Microbiol Spectr*. 2022;10(4):e00366-22. doi:10.1128/spectrum.00366-22
87. Klitting R, Kafetzopoulou LE, Thiery W, et al. Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades. *Nat Commun*. 2022;13:5596. doi:10.1038/s41467-022-33112-3

88. Omilabu SA, Badaru SO, Okokhere P, et al. Lassa Fever, Nigeria, 2003 and 2004. *Emerg Infect Dis.* 2005;11(10):1642-1644. doi:10.3201/eid1110.041343
89. Dan-Nwafor CC, Ipadeola O, Smout E, et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018. *International Journal of Infectious Diseases.* 2019;83:88-94. doi:10.1016/j.ijid.2019.03.030
90. Shaibu JO, Salu OB, Amoo OS, et al. Immunological screening of Lassa Virus among Health workers and Contacts of patients of Lassa fever in Ondo State. *Immunobiology.* 2021;226(3):152076. doi:10.1016/j.imbio.2021.152076
91. Fick SE, Hijmans RJ. WorldClim 2: new 1-km spatial resolution climate surfaces for global land areas. *International Journal of Climatology.* 2017;37(12):4302-4315. doi:10.1002/joc.5086
92. Didan K. Mod13a3 modis/terra vegetation indices monthly l3 global 1km sin grid v006. *NASA EOSDIS Land Processes DAAC.* 2015;10.
93. Abrams M, Crippen R, Fujisada H. ASTER Global Digital Elevation Model (GDEM) and ASTER Global Water Body Dataset (ASTWBD). *Remote Sensing.* 2020;12(7):1156. doi:10.3390/rs12071156
94. Schneider A, Friedl MA, Potere D. A new map of global urban extent from MODIS satellite data. *Environ Res Lett.* 2009;4(4):044003. doi:10.1088/1748-9326/4/4/044003
95. Nachtergaele F, Petri M. *Mapping Land Use Systems at Global and Regional Scales for Land Degradation Assessment Analysis Freddy Nachtergaele.* Land Degradation Assessment in Drylands; 2008. Accessed March 21, 2023. https://www.researchgate.net/profile/F-Nachtergaele/publication/265754296_Mapping_Land_Use_Systems_at_global_and_regional_scales_for_Land_Degradation_Assessment_Analysis_Version_10/links/5437eebb0cf2027cbb205c28/Map

ping-Land-Use-Systems-at-global-and-regional-scales-for-Land-Degradation-Assessment-Analysis-
Version-10.pdf

96. Weiss DJ, Lucas TCD, Nguyen M, et al. Mapping the global prevalence, incidence, and mortality of *Plasmodium falciparum*, 2000–17: a spatial and temporal modelling study. *The Lancet*. 2019;394(10195):322-331. doi:10.1016/S0140-6736(19)31097-9